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Introduction
Gout is a common disease caused by the deposition of monosodium urate (MSU) 
crystals in patients with hyperuricemia, and characterized by very painful recurrent 
acute attacks of arthritis and deposition of MSU crystals in soft tissue (tophi). Gout 
has been recognized as a clinical entity for a long period of time. Acute gout occurring 
in the first metatarsophalangeal (MTP1) joint, first identified by the Egyptians in 2640 
BC, was later recognized by Hippocrates in the 5th century BC, who referred to it as ‘the 
unwalkable disease’ (1). The first person to use the word gout (gutta quam podagram vel 
artiticam vocant – the gout that is called podagra or arthritis) was the Dominican monk 
Randolphus of Bocking, domestic chaplain to the Bishop of Chichester (1197–1258) 
(2). Through the ages gout was known as ‘the king of diseases and the disease of kings’, 
because of its association with alcohol consumption, purine-rich diet and obesity. 
Epidemiology
Gout is one of the most common rheumatic diseases with a prevalence of 1-4% in the 
adult population in developed countries (3-5). The prevalence of gout is higher in men, 
rises with age, and occurs four to ten times more often in men than in women among 
patients under the age of 65 (6). In the elderly, gout has a more equal sex distribution 
(6), possibly due to the fall of uricosuric estrogen in women after the menopause (7, 8). 
Accumulating evidence suggests an increase in the prevalence of gout in the last decades, 
which might be caused by an increased longevity and an increased prevalence of factors 
that promote hyperuricemia such as obesity, the metabolic syndrome, chronic kidney 
disease, and dietary changes (6, 9-12).
Risk factors
Many factors have been described as risk factors for the development of gout. However, 
the associations between these ‘risk’ factors and gout are almost exclusively based on 
epidemiological studies, which of course cannot proof causal relations between these 
factors and gout. Epidemiological studies show that several dietary factors might 
increase the risk of gout, such as alcohol consumption (13, 14), purine-rich meat and 
seafood intake (14-16), and consumption of fructose-sweetened soft drinks (14, 17). 
The consumption of dairy products (16), skim milk powder (18), folate, vegetables, 
and coffee are associated with a decreased prevalence of gout (14). According to 
epidemiological studies the use of thiazide and loop diuretics, but not aldosteron 
antagonists, are associated with the risk of gout (14, 19, 20). However, these results 
might be confounded by cardiovascular indications (21). 
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Male sex (6), Asian descent (22, 23), and higher age (6) are associated with higher 
prevalence of gout. Also some genes (i.e. SLC2A9, ABCG2, SLC17A3, SLC22A12 (24, 
25), HNF4G and SCL17A4 (26)) have a role in the development of gout. 
Pathogenesis
Gout is a disorder of the purine metabolism and results from MSU crystal deposition 
in and around joints, associated with hyperuricemia. The serum uric acid concentration 
is determined by the endogenous production of uric acid by synthesis and cell turnover, 
the exogenous supply via dietary intake, and renal (two-third) and intestinal (one-
third) excretion. Hyperuricemia is the result of uric acid overproduction, uric acid 
underexcretion, or a combination of the two. Hyperuricemia is defined as a serum 
uric acid concentration that exceeds the solubility at physiologic temperature and 
pH (0.38-0.40 mmol/l) (27). Although hyperuricemia is necessary to develop gout, 
it is not sufficient to cause gout. Only one cohort study from 1987 investigated the 
association between the level of serum uric acid and the cumulative incidence of gout. 
Gout occurred in just 22% of the patients with a baseline serum uric acid of more than 
0.54 mmol/l over a 5-year period (28). 
Necessary for the occurrence of gouty arthritis or tophi is the formation of MSU crystals 
when hyperuricemia is present. The formation of MSU crystals depends on the solubility 
of uric acid in joint fluid. The solubility is influenced by factors such as temperature, pH, 
level of articular dehydration, concentration of cations, and the presence of nucleating 
agents (collagen, chondroitin sulfate, and nonaggregating proteoglycans) (29). Variation 
in these factors might explain partly the preference of gout attacks in the MTP1 joint 
(the relatively low temperature of this peripheral joint) (30) and in osteoarthritic joints 
(degeneration with decreased collagen and proteoglycans) (31), and the nocturnal onset 
of the attack (articular dehydration) (32). However, these factors do not explain for 
example why gout does rarely occur in the MTP5 joint which has probably a lower 
temperature than the MTP1 joint, and gout is also rarely seen in osteoarthritic hip joints 
(31, 33). 
MSU crystals are phagocytosed as particles by monocytes/macrophages and form 
and activate the NACHT, LRR and PYD domains-containing protein 3 (NALP3) 
inflammasome. Caspase 1, recruited by the activated inflammasome, converts pro-
interleukin 1β into interleukin (IL) 1β (34-38). A second signal (for instance via long-
chain free fatty acids (36)) is needed for the production of large amounts of IL1β through 
the toll-like receptor pathway. IL1β induces recruitment of other inflammatory cells 
within the joint to produce cytokines and chemotactic factors, resulting in neutrophil 
influx into the joint and clinically in a gout attack. Gout attacks are self-limiting and 
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resolve within 7-10 days. Resolution of a gout attack involves neutrophil extracellular 
traps (NETs), which bind to MSU crystals (39). 
Clinical presentation
Typically, a patient with a gout attack has an acute painful and swollen joint, which 
is often red and warm. The onset (often at night) of the arthritis is abrupt and a gout 
attack usually affects one joint in the lower limb. Most often in primary care patients 
the MTP1 joint (57%) was involved (33). Next most frequent locations were the mid-
foot, the ankle and the knee (31). In 86% of the patients the lower leg was affected (33). 
Although a monoarthritis of MTP1 is the hallmark of gout, it is unknown how often a 
MTP1 arthritis is actual gout. In case of gout-suggesting MTP1 arthritis it is important 
to diagnose correctly, because management depends on it for both situations, if it turns 
out to be gout or non-gout (for example rheumatoid arthritis).
We designed a prospective follow-up study on the prevalence of gout and other diseases 
in patients with monoarthritis of MTP1, and on the correctness of the gout diagnosis 
by physicians in these patients (chapter 2).
The arthritis attacks are often recurrent. Some patients develop tophi that can lead to 
permanent joint damage. Tophi can be found in or close to joints, in bursas, tendon 
sheaths, and in articular cartilage (40). Clinical experience shows that in some patients 
later in the course of the disease the gout attacks can occur more often, and it takes more 
days before the attack is resolved. Then the arthritis is more frequently polyarticular and 
spreads to the upper limbs (31, 41). 
Diagnosis
The gold standard for diagnosing gout is the identification of MSU crystals in synovial 
fluid or in a tophus by polarization light microscopy (42, 43). A correct positive 
diagnosis of gout is important for an adequate management, both pharmacologically 
(i.e. anti-inflammatory or uric acid lowering drugs) and non-pharmacologically (i.e. 
lifestyle advices and assessment of risk factors). However, a correct negative diagnosis is 
also important to lead to a different rheumatic diagnosis, such as calcium pyrophosphate 
dehydrate arthritis or rheumatoid arthritis. The accuracy of the gold standard has been 
tested in only a few studies. The sensitivity of detection of MSU crystals by observers 
was 69% with a specificity of 97% (44). After training the sensitivity of the detection of 
MSU crystals can become 95% with a specificity of 97% (45). Physicians involved in 
analyzing synovial fluid in routine daily care identified MSU crystals in an online test 
with images in 81% correctly (46). 
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Although there is a gold standard, in many situations, particularly in primary care and 
at emergency departments, synovial fluid analysis is often not possible or not available. 
Polarization light microscopes are expensive and almost only available at rheumatology 
departments. But approximately 90% of the gout patients are diagnosed and treated by 
primary care physicians (47). Primary care physicians diagnose gout without synovial 
fluid analysis, based on clinical signs and symptoms, which has demonstrated to have a 
limited predictive value (33). 
The use of synovial fluid analysis could be extended if aspirated synovial fluid could be 
stored for delayed analysis. Then the general practitioner or other non-rheumatologist 
could send synovial fluid to a rheumatology department for analysis within some days or 
weeks for a definite diagnosis. An important condition is that the delayed analysis is still 
reliable. In clinical practice most synovial fluid is aspirated from the affected joint during 
a gout attack. A longstanding opinion is that synovial fluid should be analyzed with a 
polarization microscope rapidly after aspiration, because the formation and solubility 
of MSU crystals might be affected by pH and temperature. A systematic review has 
shown that MSU crystals can also be detected in synovial fluid which has been stored 
for a maximum of 8 weeks (48). It is unknown until how long and in which storage 
conditions MSU crystals still can be reliably identified. 
We performed a study in which we have analyzed synovial fluid samples for MSU 
crystals after long-term and varying storage conditions (chapter 3).
If facilities to aspirate and investigate synovial fluid are not available gout is diagnosed 
based on clinical signs and symptoms. Several criteria sets have been developed to 
improve the validity of the clinical diagnosis, such as the 1977 American College 
of Rheumatology criteria (49), which showed a limited sensitivity (90%; 79%) and 
specificity (64%; 70%) in primary (50) and secondary care (51) in MSU crystal-proven 
gout patients, respectively (52). In 2015, new gout classification criteria were formed 
in an American College of Rheumatology/European League Against Rheumatism 
collaborative initiative. The sensitivity and specificity of the criteria are high (92 and 
89%, respectively) in secondary and tertiary care (52), with a comparable specificity 
(84 to 95%), but reduced sensitivity (68%) in primary care (53). A diagnostic rule to 
diagnose gout without synovial fluid analysis developed in a primary care population 
of MSU crystal-proven gout patients was published in 2010 (33). This easy-to-use 
decision rule consists of six clinical signs and one laboratory parameter (i.e. uric acid). 
Even in secondary care polarization microscopes are not always available, for example 
in busy emergency departments, in small solo rheumatology practices or in general in 
developing countries (54-57). Then this diagnostic decision rule could also be of use, if 
sufficiently valid in the secondary setting. However, this is unknown.
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We designed a prospective diagnostic population study on the validation of this 
diagnostic rule for diagnosing gout without joint fluid analysis in a secondary care 
population (chapter 4 and chapter 4a).
Comorbidities in gout
Comorbidities as hypertension (58), chronic kidney disease, cardiovascular diseases (59-
63), the metabolic syndrome (58, 64), diabetes (64, 65), obesity (58), hyperlipidemia 
(58), sleep apnea (66) and early menopause (7) are highly prevalent in patients with 
gout if compared to control patients. Nowadays, especially the association between gout 
and cardiovascular diseases is an extensive research field (59-63, 67, 68). 
Most studies investigated the association between hyperuricemia (with or without 
gout) and cardiovascular diseases. Hyperuricemia is associated with an increased risk of 
coronary heart diseases and stroke incidence and mortality related to both diseases, after 
correction for traditional risk factors for cardiovascular diseases (59, 60). The cardiac 
mortality risk increased with 12% per increase of the serum uric acid of 0.059 mmol/l 
(60). In women there was a stronger association than in men (59, 60), and higher 
levels of hyperuricemia are stronger risk factors than lower levels of hyperuricemia (69). 
Interestingly, several studies observed a J-curve relationship between serum uric acid 
level and cardiovascular disease or all-cause mortality (70, 71): a low serum uric acid 
level might be associated with a higher mortality, because uric acid can play a protective 
antioxidant role (72). An important limitation of research on the association between 
hyperuricemia and cardiovascular diseases is that the definition of hyperuricemia 
differed between several studies and the uric acid level was not always corrected for sex. 
Also, patients with hyperuricemia could be symptomatic (i.e. gout) or asymptomatic. 
However, it is likely that the conclusions from studies about patients with hyperuricemia 
are also valid in patients with gout, because gout patients always have hyperuricemia.
Although most of the literature focuses on the relation between hyperuricemia and 
cardiovascular diseases, some studies also investigated the association between gout and 
cardiovascular diseases. Patients with gout had a higher incidence of heart failure (61) 
and myocardial infarction (68) compared to those without gout. Several prospective 
cohort studies showed that mortality rates from cardiovascular diseases and overall 
mortality were higher in gout patients compared to non-gout patients (61-63, 67, 73). 
Remarkably, gout is a stronger risk factor for cardiovascular diseases and mortality than 
hyperuricemia alone (62, 63), which was even more evident in patients with tophaceous 
gout (69). Unfortunately, in this research gout was often not diagnosed by identification 
of MSU crystals, but on self-report. In MSU crystal-proven gout the association might be 
stronger than in gout otherwise diagnosed because there might be false-positives within 
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the self-reported gout patients. Therefore the association of gout and cardiovascular 
diseases can be underestimated.
The pathophysiological pathways that link gout and cardiovascular diseases are not fully 
clear. Accumulating evidence shows that xanthine oxidase plays a central role in this. Uric 
acid is formed mainly by the enzyme xanthine oxidase, which converts hypoxanthine 
and oxygen into uric acid, superoxide and other oxidative free radicals. Free radicals 
induce oxidative stress in the vessel wall, which leads to endothelial dysfunction and in 
the end to cardiovascular diseases (74, 75). Upregulation of xanthine oxidase activity 
rather than decreased renal excretion of uric acid is an important factor underlying 
high serum uric acid levels in heart failure patients (76). And several studies suggest 
that allopurinol, a xanthine oxidase inhibitor, has cardiovascular protective effects, 
such as improvement of endothelial function (77) and reduction of blood pressure 
(78, 79). In patients with chronic stable angina allopurinol reduced the time to chest 
pain and increased the total exercise time (80). Allopurinol also reduced mortality in 
heart failure patients (81-84) and in gout patients (85). One study investigated the 
effect of allopurinol on cardiovascular outcome: it was associated with a reduced risk 
of myocardial infarction (86). On contrary, benzbromarone (87) and probenecid (88), 
both uricosurica, did not have these beneficial cardioprotective effects, which underlines 
the potential role of xanthine oxidase in cardiovascular diseases.
A different pathway that might link gout to cardiovascular diseases is based on chronic 
systemic inflammation. In patients with other chronic inflammatory diseases, such as 
rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, a higher occurrence of 
cardiovascular morbidity and mortality has been found (89-91). It is generally presumed 
that chronic systemic inflammation is importantly involved in the pathophysiology of 
atherosclerosis. Like in other rheumatic diseases chronic inflammation could in this way 
also contribute to the development of cardiovascular comorbidity in gout patients. Some 
evidence is found that in patients with hyperuricemia or gout low-grade chronic systemic 
inflammation is present: serum uric acid levels were associated with C-reactive protein 
levels, TNFα levels and IL6 levels (92). Typical gout signs seen with ultrasonography 
are present in clinically silent joints of patients with hyperuricemia or gout (93), which 
might imply that also in-between gout attacks low-grade local inflammation is present. 
Tophaceous gout was a stronger risk factor for cardiovascular diseases and mortality than 
non-tophaceous gout (69), suggesting that in a severe form of gout with widespread urate 
deposition more ‘atherosclerotic inflammation’ might be present. Various studies have 
described the presence of local inflammatory mediators, such as the proinflammatory 
cytokine CXCL8, in synovial fluid during gout attacks (94-96). However, similar 
attempts to investigate the presence of inflammatory mediators in serum, either during 
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gouty arthritis or in the intercritical phase of the disease, are lacking. CXCL8 has an 
important role in the pathogenesis of gout, because it is a neutrophil chemotactic factor 
and neutrophil influx is a hallmark of gouty arthritis. Further, CXCL8 was earlier found 
in atherosclerotic vessel walls (97-101). Increased serum CXCL8 levels are a predictor 
for clinical outcome in patients with coronary artery disease (102), and are present in 
diabetes mellitus patients (103) and obese patients (104). Therefore, CXCL8 might not 
only locally be important for the induction of gouty arthritis, but circulating CXCL8 
could also have a role in the association between gout and comorbidities, such as 
cardiovascular diseases.
We investigated if systemic proinflammatory cytokines, especially CXCL8, are present 
in patients with gout and if they are associated with the co-occurrence of comorbidities 
(chapter 5). 
As described before allopurinol has cardiovascular protective effects. Xanthine oxidase 
inhibition and therewith reduction of chronic systemic inflammation is often mentioned 
as the mechanism of these positive effects (105). However, lowering of chronic systemic 
inflammation, associated with proinflammatory cytokines like CXCL8, could be a part 
of the mechanism that explains the favorable effects of allopurinol. 
We conducted a pilot study on the effect of allopurinol on CXCL8 levels in patients 
with gout (chapter 6). 
Chronic inflammation activates the immune system, leading to an increased demand 
for immune cells and forcing cell replication. This can eventuate a state of replicative 
senescence in cells, i.e. cells can no longer divide to form new cells. The most used 
marker for replicative senescence is telomere length (106). A significantly increased 
relative risk for developing cardiovascular diseases was found in patients with the shortest 
telomeres (107). As explained in detail before, gout patients have an increased risk for 
cardiovascular comorbidity. The presence of chronic inflammation in gout patients 
could accelerate senescence, and thereby enhance this risk for cardiovascular diseases. 
However, studies on this hypothesis are lacking.
We studied the telomere lengths and its association with comorbidities (i.e. cardiovascular 
diseases) in gout patients (chapter 7).
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Treatment and prognosis
With a correct diagnosis gout should also be managed correctly. Standard treatment 
consists of anti-inflammatory drugs for gout attacks, sometimes followed by long-term 
preventive urate lowering therapy. Although the therapeutic management of gout is not 
a subject of this thesis, it will be described shortly.
Acute gout attacks are treated with non-steroidal anti-inflammatory drugs (NSAIDs), 
colchicine, oral prednisone, or intra-articular or intramuscular glucocorticoids. 
Unfortunately, there are only a few trials which compare the efficacy and safety of 
these therapeutics in gout patients (108-111). Because of the lack of trials, the choice 
which anti-inflammatory therapy is prescribed is mainly based on comorbidity and 
comedications. IL1β blockers such as canakinumab (112), anakinra (113-115), and 
rilonacept (116-120) are new therapeutic opportunities in patients with gouty arthritis. 
However, these new therapeutics are expensive, and should only be prescribed in patients 
with frequent gout attacks who failed or have contra-indications for the traditional anti-
inflammatory drugs. Trials concerning the efficacy of non-pharmacological interventions 
for gout attacks are even more rare, probably due to ethical and practical difficulties to 
set up these type of trials (121). Only one trial was performed which shows that local ice 
therapy can be useful during gout attacks (122).
Preventive uric acid lowering therapy is indicated in patients with two or more gout 
attacks per year, tophaceous gout, or a history of uric acid urolithiasis (123-125). The 
decision whether to start preventive uric acid lowering therapy or to accept frequent gout 
attacks and/or tophi should always be made in accordance with the patient. The aim of 
the uric acid lowering therapy is to decrease the frequency of gout attacks (126, 127) 
and/or to reduce tophi (128) by sufficiently reducing the serum uric acid level. The target 
serum uric acid level should be at least below 0.36 mmol/l (124). A lower target serum 
uric acid of 0.30 mmol/l can be aimed for in case of severe gout (for instance tophaceous 
gout) (123, 129). Based on evidence and experience the first choice uric acid lowering 
agent is the xanthine oxidase inhibitor allopurinol (123-125, 130). If the target serum 
uric acid level cannot be reached by an appropriate dose of allopurinol, allopurinol can 
be switched to an uricosuric, such as benzbromarone (128, 131), or the newer xanthine 
oxidase inhibitor febuxostat (132). Also combination of allopurinol and an uricosuric is 
a good treatment option. A new uricase derivative pegloticase is proven to be useful in 
patients who are refractory to or intolerant for conventional therapy (133-137). Uricases 
should be administered intravenously with a risk of infusion reactions, and there always 
remains a risk for antibody formation due to the conjugation to proteins. The selective 
uric acid reabsorption inhibitor (SURI) lesinurad might be another future treatment 
option (138-140).
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The dose of the uric acid lowering medications should be carefully increased to reduce 
adverse effects, and should be titrated based on serum uric acid levels (123-125, 130). 
It is generally accepted that uric acid lowering therapy should be started under several 
months of prophylactic anti-inflammatory medications (colchicine or NSAIDs) to 
prevent paradoxal gout attacks at the beginning (123-125), although there are no studies 
to prove this. The uric acid lowering therapy should be continued lifelong. 
In addition to the uric acid lowering therapy some other pharmacological measures 
can be helpful to reduce serum uric acid. When a gout patient is also diagnosed with 
hypertension, losartan could be considered as antihypertensive treatment, because of its 
small uric acid lowering effect (141). Vitamin C, a safe supplement, might have a very 
small uric acid lowering effect (142, 143), although a small randomized controlled trial 
in gout patients could not confirm this (144). 
Additional non-pharmacological measures, like dietary advices, to reduce serum 
uric acid may be useful, but their uric acid lowering effects are small (10-18%) and 
therapeutically insufficient (i.e. no reduce of the frequency of gout flares) in most 
patients (14). Observational studies showed that the intake of purine-rich meat and 
seafood, fructose-rich soft drinks, and alcohol should be reduced, and dairy intake 
and the consumption of vegetables should be encouraged (14, 123, 124, 145). Trials 
concerning the efficacy of non-pharmacological interventions to lower serum uric acid 
are also lacking. The only trial of dietary intervention in gout patients suggested that 
skim milk powder enriched with glycomacropeptide and G600 milk fat extract might 
reduce the frequency of gout flares (18). 
Gout is a potentially curable disease. Unfortunately, the management of gout patients 
is often insufficient (6, 146-150). An important reason is the limited use of uric acid 
lowering therapy. Only 30-60% of the patients are still prescribed allopurinol one year 
after the start of the therapy (3), and only 17% of the gout patients might be fully 
adherent to allopurinol therapy (151). The poor adherence is often, unfairly, blamed 
on gout patients unwilling to take uric acid lowering therapy. Lack of appropriate 
information from their doctor is an important factor which plays a role in the poor 
adherence. An observational study showed that patient education, individual lifestyle 
advice and slow upward titration of uric acid lowering therapy according to serum uric 
acid levels can improve the adherence to uric acid lowering therapy (152). 
Acute gout attacks and the presence of tophi account for a major component of the 
reported decreased health-related quality of life in gout patients, and are associated 
with decreased work productivity which leads to an economic burden for the societ 
Chapter 1
22
(153-155). This emphasizes the importance of the effective management of gout. Urate 
lowering therapy is cost-effective when patients have two or more recurrent attacks per 
year (156). 
Objectives and research questions of the thesis
Objectives
The main objectives of this thesis are to obtain more insight into and evidence about: 
- a correct diagnosis of gout,
-  the role of chronic systemic inflammation in gout and in the association between gout 
and comorbidities like cardiovascular diseases.
The first objective is investigated by prospective, clinical, diagnostic research described 
in chapters 2, 4 and 4a, and by basic research in chapter 3. Chapters 5, 6 and 7 explore 
the second objective by basic, immunological research. 
Research questions
The following research questions are answered in this thesis.
Chapter 2:
- What is the validity of the clinical diagnosis of gout in arthritis of the MTP1 joint?
-  What is the prevalence of other diagnoses than gout in MTP1 arthritis after follow-up?
-  Can clinical signs and symptoms be identified that discriminate between patients with 
and without gout in MTP1 arthritis?
Chapter 3:
- Is delayed synovial fluid analysis for diagnosing gout reliable?
- What is the best temperature to store synovial fluid for delayed analysis?
Chapter 4 (and chapter 4a):
-  Is there a valid method for diagnosing gout based on clinical signs and symptoms in 
secondary care, if synovial fluid analysis is not possible or available?
- If this method is available, how should it be used in clinical practice?
Chapter 5:
-  Are inflammatory cytokines increased in serum of gout patients during arthritis and in 
the intercritical phase?
-  If these inflammatory cytokine levels are increased, are they associated with 
cardiovascular diseases?
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-  If these inflammatory cytokine levels are increased, are there underlying proteins which 
are associated with these cytokine levels?
-  If these underlying proteins are present, are they associated with cardiovascular diseases?
Chapter 6:
-  What is the effect of allopurinol treatment on inflammatory cytokine levels in patients 
with gout?
-  What is the mechanism that can explain the cardiovascular protective effects of 
allopurinol?
Chapter 7:
-  Do gout patients have shorter telomere lengths as an indicator for accelerated replicative 
senescence?
-  Is there an association between accelerated replicative senescence and the occurrence of 
cardiovascular diseases in gout patients?
Chapter 8 discusses the overall results of this thesis.
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Abstract
Objectives
Arthritis of the first metatarsophalangeal joint has been considered pathognomonic for 
gout, but it is unknown how frequently other forms of arthritis occur in this joint. The 
aims were to determine the validity of the general practitioner’s clinical diagnosis using 
joint fluid analysis as the reference test, the prevalence of other diagnoses than gout, and 
the signs and symptoms that discriminate between gout and non-gout patients.
Methods
This prospective cohort study comprised primary care patients with monoarthritis of 
the first metatarsophalangeal joint. After patient recruitment by general practitioners, 
patient characteristics were collected by a rheumatologist. Joint fluid was analyzed for 
the presence of monosodium urate crystals. If crystals were absent, patients entered a 
follow-up period of 6 years, or until a definite diagnosis. If during follow-up crystals 
were identified, the patient was classified as already having gout at baseline assessment.
Results
159 primary care patients were included. At baseline the clinical diagnosis was gout in 
98%. The positive and negative predictive values of the diagnosis of gout were 0.79 and 
0.75, respectively. After follow-up 77% had gout, 8% had another rheumatic disease, 
and 15% had a transient unspecified monoarthritis. Gout patients had discriminating 
signs and symptoms from non-gout patients.
Conclusions
Gout is an important but certainly not an exclusive cause of arthritis of the first 
metatarsophalangeal joint.
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Introduction
Acute gout occurring in the first metatarsophalangeal (MTP1) joint was already among 
the earliest diseases to be recognized as podagra (1). Nowadays MTP1 arthritis is still 
considered to be the hallmark of gout. 
Monoarthritis is a common form of arthritis in primary care. The differential diagnosis 
of monoarthritis is extensive. In at least 20% of the primary care patients it is not 
possible to reach a definitive diagnosis, i.e. an unspecified monoarthritis (2). Within 
the group of monoarthritis gout is the most prevalent diagnosis (57%) (2). One to 
two percent of the population has been identified as having gout (3). The prevalence of 
MTP1 arthritis in patients with monoarthritis is about 40% (2). The initial attack of 
gout affects the MTP1 joint in 56-78% of the patients. This joint is involved at some 
point in the course of gout in 59-89% (4, 5).
Despite the fact that gout is the most frequent cause of a monoarthritis and that gout 
occurs most often in the first MTP joint, it is unknown how often other forms of 
arthritis occur in MTP1. A definitive diagnosis is important because of therapeutic, 
prognostic and comorbid, i.e. cardiovascular (6-8), consequences. The consequences of 
the wrong diagnosis of gout are incorrect information to the patient, incorrect estimation 
of the prognosis, and prescription of incorrect therapeutic measures. The latter implies 
useless uric acid lowering therapy, and failure to offer anti-rheumatic therapy in case of 
rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
The first aim of this study was to determine the validity of the general practitioner’s (GP’s) 
clinical diagnosis gout in the MTP1 joint using the identification of monosodium urate 
(MSU) crystals in joint fluid as the reference test. Secondly, to determine the prevalence 
of other forms of monoarthritis in the MTP1 joint. The third aim was to identify the 
clinical signs and symptoms that discriminate between patients with and without gout. 
Methods
Study population
This is a subanalysis and an extension of a prospective cohort study performed from 
March 24, 2004 until July 14, 2007 to develop a diagnostic rule for GPs to diagnose gout 
without joint fluid analysis (2). Patients with signs and symptoms of a monoarthritis of 
the MTP1 joint according to a GP and with a prior probability of gout were included. 
The GP practices that participated in the study covered 180,000 to 200,000 persons. In 
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the Netherlands all inhabitants are registered with a personal GP who provides primary 
care for 2,000 to 3,000 people. The GP functions as a gatekeeper and refers patients on 
indication to a hospital for secondary care. 
GPs included patients during regular office hours (Monday to Friday, 8 am to 6 pm). 
The GPs referred patients to one regional research centre (Department of Rheumatology, 
Rijnstate Hospital, Arnhem, the Netherlands).  
Baseline assessment
Within 24 hours of presentation to the GP, the patients were examined, with a few 
exceptions, by the same rheumatologist. All patients had a standardized interview and 
a physical examination. Table 1 gives an overview of the patient’s characteristics which 
were collected. The first MTP joint of each patient was aspirated and the joint fluid was 
analyzed with a polarization microscope for the presence of MSU crystals. When no 
joint fluid could be aspirated the patient was classified as not having gout. When MSU 
crystals could not be identified, additional clinical and laboratory investigations were 
performed to diagnose or exclude other forms of arthritis, including IgM rheumatoid 
factor, anticyclic citrullinated peptide antibody, radiographs, and on indication 
antinuclear antibody, antistreptolysin titer, anti-DNase B, or Borrelia IgM and IgG 
antibodies. In the case of a definite diagnosis fulfilling the accepted criteria of various 
rheumatic diseases the follow-up was stopped.
 
After referral of the patient the GP faxed to the regional research centre whether he 
thought the MTP1 arthritis was gout or non-gout. The clinical diagnosis of the GP 
remained concealed from the researchers during the follow-up period.
Follow-up
In case of non-gout the patient entered a follow-up period at the regional research 
centre for a period of at least 1 year until July 14, 2007. During that year every non-
gout patient with a new episode of any arthritis was re-evaluated, including joint fluid 
analysis for the presence of MSU crystals. 
After this initial follow-up period, patients were additionally followed-up for 5 years by 
their GP through June 30, 2012. In June 2012 the GPs were contacted and in addition 
medical hospital records were re-evaluated to see whether a definite diagnosis has been 
established. 
If MSU crystals were identified during the follow-up period, the non-gout patient was 
retrospectively classified as already having gout at baseline assessment. The eventual initial 
false-negative result for gout of the joint fluid analysis was then changed to a positive result.
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Table 1. Patients’ characteristics of patients with MTP1 arthritis with and without gout.
Patient characteristics Gout (n=123) Non-gout 
(n=36)
P valuef Odds ratio 
(95% confidence 
interval)
Age, years, mean (SD) 59.2 (13.6) 55.0 (14.1) 0.12 0.98 (0.95-1.01)
Male sex, No. (%) 104 (85) 19 (53) 0.00 4.90 (2.16-11.09)
Onset, No. (%)
-  Within hours 48 (39) 19 (53) 0.14 0.57 (0.27-1.21)
-  Within 1 day 97 (79) 30 (83) 0.56 0.75 (0.28-1.98)
Patient history, No. (%)
-  Patient-reported arthritis attack 76 (62 13 (36) 0.01 2.86 (1.32-6.19)
-  Arthritis always in the same joint 41 (54) 10 (77) 0.13 0.35 (0.09-1.38)
-  Patient-reported gout 61 (50) 8 (22) 0.01 3.44 (1.46-8.15)
Medication use, No. (%)
-  Diuretics 38 (31) 5 (14) 0.05 2.77 (1.00-7.68)
-  Antiplatelet agents, acetylsalicylic acid 12 (10) 1 (3) 0.67 1.14 (0.62-2.11)
-  Cardiovascular or antihypertensive drugs 75 (61) 9 (25) 0.00 4.69 (2.03-10.82)
Family history of gout, No. (%) 30 (24)a 8 (22)b 0.67 1.20 (0.52-2.72)
Comorbidity, No. (%)
-  Diabetes 8 (7) 2 (56) 0.84 1.18 (0.24-5.83)
-  Hypertension 60 (49) 6 (17) 0.00 4.76 (1.85-12.25)
-  ≥1 cardiovascular diseases g 41 (33) 3 (8) 0.00 5.50 (1.59-19.01)
-  Hypertension or ≥1 cardiovascular diseases 77 (63) 8 (22) 0.00 5.86 (2.46-13.94)
-  Renal stones 10 (8) 0 (0) NA NA
Alcohol consumption, No. (%)
-  Any 69 (56) 20 (56) 0.91 0.96 (0.45-2.05)
-  Beer 47 (38) 5 (14) 0.01 3.71 (1.35-10.23)
-  Wine 15 (12) 15 (42) 0.00 0.19 (0.08-0.44)
-  Liquor 12 (10) 1 (3) 0.22 3.68 (0.46-29.30)
-  ≥7 units per week 52 (42) 17 (47) 0.60 0.82 (0.39-1.73)
Joint redness, No. (%) 117 (95) 33 (92) 0.44 1.77 (0.42-7.47)
Tophus, No. (%) 11 (9) 0 (0) NA NA
Psoriasis, No. (%) 7 (6) 1 (3) 0.68 1.14 (0.86-1.50)
Body mass index, kg/m2
-  mean (SD) 29.1 (4.1) 28.4 (7.0) 0.41 0.97 (0.89-1.05)
-  >30, No. (%) 47 (38) 10 (28) 0.25 1.61 (0.71-3.63)
-  >25, No. (%) 107 (87) 26 (72) 0.04 2.57 (1.05-6.32)
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Systolic blood pressure, mmHg
-  mean (SD) 145.2 (23.6) 142.6 (23.0) 0.56 1.00 (0.98-1.01)
-  >140 mmHg, No. (%) 52 (42) 16 (44) 0.82 0.92 (0.43-1.94)
Diastolic blood pressure, mmHg
-  mean (SD) 85.1 (12.1) 83.8 (13.3) 0.56 0.99 (0.96-1.02)
-  >90 mmHg, No. (%) 34 (28) 10 (28) 0.99 0.99 (0.43-2.28)
Serum uric acid level, µmol/l
-  mean (SD) 481.8 (101.1) 362.8 (101.1) 0.00 0.00 (0.00-0.00)
-  >349.7, No. (%) 120 (98) 16 (44) 0.00 50.00 (13.35-187.33)
Creatinine level, µmol/l
-  mean (SD) 97.2 (44.2) 79.6 (17.7) 0.00 0.97 (0.95-0.99)
-  >105.2, No. (%) 34 (28) 3 (8) 0.02 4.20 (1.21-14.61)
Glomerular filtration rate, ml/min/1.73m²
-  mean (SD) 72.9 (25.0) 80.5 (15.0) 0.09 1.01 (0.99-1.03)
-  <90, No. (%) 94 (76) 22 (61) 0.07 2.06 (0.94-4.54)
-  <60, No. (%) 37 (30) 3 (8) 0.01 4.73 (1.37-16.41)
Erythrocyte sedimentation rate, mm/min
-  mean (SD) 19.6 (15.0)c 16.4 (11.6) 0.25 0.98 (0.95-1.01)
-  >20 for men or >30 for women, No. (%) 41 (33)c 10 (28) 0.51 1.32 (0.58-2.99)
C-reactive protein, mg/dl
-  mean (SD) 2.1 (2.9)d 1.5 (2.3)e 0.22 0.99 (0.97-1.01)
-  >1, No (%) 68 (55)d 9 (25)e 0.00 3.70 (1.59-8.61)
MTP1: first metatarsophalangeal; NA: not applicable because tophus and renal stones presence completely coincided 
with monosodium urate crystal presence; SD: standard deviation.
an=121; bn=35; cn=122; dn=119; en=34; NA=not applicable.
fBased on the differences in both groups after univariate logistic regression analysis.
gAngina pectoris, myocardial infarction, heart failure, cerebrovascular accident, transient ischaemic attack, or peripheral 
vascular disease.
Statistical analysis
For the comparison of the GP’s clinical diagnosis with the identification of MSU 
crystals, we established the diagnostic test characteristics (sensitivity, specificity, positive 
and negative predictive values, and positive and negative likelihood ratios) using 2 x 2 
tables. For the signs and symptoms we used descriptive statistics, with the presence of 
MSU crystals as the dependent variable. Results for quantitative variables are reported 
as the means ± standard deviation. Results for qualitative variables are shown as the 
number and percentages of patients per category. The gout and the non-gout groups 
were compared using univariate logistic regression. All statistical tests were performed 
using PASW Statistics 18.
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Results
Ninety-three GPs recruited 381 primary care patients with signs and symptoms of 
monoarthritis and a prior probability of gout. Of them 159 had monoarthritis of the 
fi rst MTP joint. Th ey form our study group. Th eir mean age was 58.2 (13.8) years, and 
123 (77.4%) patients were male. Th e mean pain score measured with a visual analog 
scale from 0 to 100 was 53.7 (22.7). 
At baseline in 118 (74.2%) patients MSU crystals were identifi ed. During follow-up in 
5 additional patients, MSU crystals were found in the joint fl uid of recurrent arthritis. 
Nineteen of the 159 (11.9%) patients died in the follow-up period. Figure 1 shows the 
diagnoses at baseline, during follow-up, and after follow-up. 
 
AFTER FOLLOW UP 
DURING 
FOLLOW UP 
BASELINE 
155 GP gout 4 GP non-gout 
117 MSU 38 non-MSU 1 MSU 3 non-MSU 
118 MSU 
41 non-MSU 
31 non-MSU and no 
diagnosis 
10 diagnoses other than 
gout 
5 MSU during follow 
up 
2 diagnoses other than 
gout during follow up 
123 MSU  
(16 died) 
24 non-MSU and  
no diagnosis  
(3 died) 
12 diagnoses other than 
gout 
Figure 1. Diagnoses in patients with arthritis of the fi rst metatarsophalangeal joint at baseline, during follow-up, and 
after follow-up. MSU: identifi cation of monosodium urate crystals in joint fl uid; GP: general practitioner’s diagnosis.
Validation of the clinical GP diagnosis
In 155 (97.5%) of the 159 patients with MTP1 arthritis the GPs thought that the probable 
diagnosis was gout, based on clinical signs and symptoms. Comparison of the GP diagnosis 
of gout to the gold standard of MSU-crystal identifi cation showed a sensitivity of 0.99, 
a specifi city of 0.08, a positive predictive value of 0.79, and a negative predictive value of 
0.75. Th e positive and negative likelihood ratios were 1.1 and 0.1, respectively.
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Other rheumatic diagnoses in MTP1 arthritis
At baseline 10 (6.3%) of the 159 patients had a different rheumatic disease than gout 
and 31 (19.5%) had an unspecified monoarthritis. After follow-up, MSU crystals were 
found in 5 (3.1%) patients who were then classified as gout; 12 (7.5%) patients fulfilled 
the criteria for various rheumatic diseases, and 24 (15.1%) of them had an unspecified 
monoarthritis (table 2). Osteoarthritis was the most prevalent diagnosis after gout. 
Clinical differences between gout and non-gout
The clinical differences between patients with and without gout are shown in table 1. 
The following signs and symptoms were significantly more frequent in patients with 
MSU crystal-proven gout after the univariate analysis: male sex, a previous arthritis, 
patient-reported gout, the use of diuretics, the use of cardiovascular or antihypertensive 
drugs, hypertension and/or cardiovascular disease, beer consumption, BMI >25 kg/m2, 
serum uric acid >349.7 µmol/L, serum creatinine >105.2 µmol/L, glomerular filtration 
rate <60 ml/min, and C-reactive protein >1 mg/dl (P<0,05). 
Discussion
Like their predecessors in Antiquity, physicians in the modern era diagnose gout in 
almost 100% of patients presenting with MTP1 arthritis. Although gout was the 
most prevalent diagnosis, this study shows that in one quarter of the patients MTP1 
arthritis was the sign of a different diagnosis. In our patient cohort we found, if no MSU 
crystals had been identified, MTP1 arthritis as a manifestation of systemic rheumatic 
diseases as rheumatoid arthritis, psoriatic arthritis, pseudo-gout, arthritis secondary 
to an inflammatory bowel disease, and palindromic rheumatism. This shows that the 
differential diagnosis of MTP1 arthritis is comparable to that of mono-, oligo- or 
polyarthritis. Our study identifies several clinical signs and symptoms that can help 
to distinguish gout from non-gout, which are male sex, a previous arthritis, patient-
reported gout, the use of diuretics, the use of cardiovascular or antihypertensive drugs, 
hypertension and/or cardiovascular disease, beer consumption, high BMI, high serum 
uric acid, high serum creatinine, low glomerular filtration rate, and high C-reactive 
protein. 
The literature on monoarthritis in general and in particular on MTP1 arthritis is very 
limited. The papers about monoarthritis in general consist mainly of literature studies 
and expert opinions (9-20). Papers concerning monoarthritis of MTP1 are scarce and 
largely based on case reports (21-27). A little more literature can be found on MTP1 
arthritis as part of oligo- or polyarthritis in various rheumatic diseases (28-32).
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The sensitivity of the clinical GP diagnosis is high, but the specificity of the GP diagnosis 
is very low. The latter shows that a patient with non-gout MTP1 arthritis is rarely 
classified by the GP as having non-gout. 
In 15% of our patients the cause of the MTP1 arthritis was unknown. Compared to the 
literature this percentage of unspecified arthritis is low (33, 34). The majority of patients 
(67%) with unspecified arthritis remained asymptomatic during follow-up and in only 
23% a definite diagnosis was established. Gout is a recurrent disease and 32% of the 
patients experience another attack within 5 years of the first non-crystal proven gout 
attack (35). Gout cannot be fully excluded in our unspecified arthritis patients, but, 
because of the recurrent nature of gout, 6 years of follow-up makes it unlikely. 
Our data show that in contrast to earlier reports (36, 37) serum uric acid is almost 
always (98%) elevated during a MTP1 gout attack. A possible explanation is that gout 
in the present study was always based on MSU crystal identification, while other studies 
accepted clinical criteria for the diagnose of gout. As we demonstrated in the non-gout 
MTP1 arthritis group, the serum uric acid was often (56%) within the normal range 
during an acute attack. 
The mean pain score measured with a visual analog scale from 0 to 100 in the gout and 
non-gout groups was 54.3 (22.4) and 51.4 (23.84) (P=0.65), respectively. The pain 
score cannot be used to differentiate between gout and non-gout.
A major strength of our study is that it is the first large group of primary care patients 
with MTP1 arthritis. Our primary care cohort is representative of the population in 
which gout is first diagnosed as all eligible patients from primary care were referred, in 
contrast to normal practice when GPs refer only about 10% of the patients suspected of 
having gout to a rheumatology department (38). 
There are several limitations of our study. No multivariate logistic regression analysis was 
performed on our data, because the non-gout group was too small to get reliable results. 
However, next to the diagnostic rule for gout (2), clinical signs and symptoms were 
identified to help clinicians in their daily practice to distinguish gout from non-gout. 
Another limitation is that in 15% of the patients no MSU crystals were found and no 
other diagnosis was established. In 29% of these patients joint fluid was not obtained or 
unsurely obtained during aspiration. The percentage is higher than in the total group of 
MTP1 arthritis patients (7%). Joint fluid was aspirated and analyzed for the presence of 
MSU crystals by a well-trained rheumatologist, which makes skills-related reasons for 
not obtaining joint fluid or not finding MSU crystals unlikely. The sensitivity of crystal 
detection is 95% with a specificity of 97% (39). The probable reason for the higher 
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percentage of failed aspiration in the unspecified arthritis group is that the arthritis was 
milder in these patients. A third limitation could be that in our study we did not use 
X-ray or ultrasound as tools to support the diagnostic process of the presented arthritis. 
However, the real diagnostic performance of them is unknown or e.g. with respect to 
ultrasound to diagnose gout insufficiently sensitive (40). The gold standard to diagnose 
gout remains identification of MSU crystals in joint fluid.
In conclusion, our findings show that gout is a prominent but certainly not an exclusive 
cause of MTP1 arthritis. Gout is the correct diagnosis in only 77% of the patients with 
MTP1 arthritis while GPs suppose gout to be the diagnosis in 98% of these patients. 
The differential diagnosis of MTP1 arthritis is extensive. This study advocates the need 
to validate the diagnosis maximally by the use of clinical signs and symptoms in order 
to distinguish between gout and non-gout, and to refer the patient to secondary care for 
joint fluid analysis in cases of diagnostic doubt, taking into account the therapeutic and 
prognostic consequences. 
Table 2. Other rheumatic diagnoses than gout in patients with MTP1 arthritis after 6 years follow-up. 
Other diagnoses than gout in patients with MTP1 arthritis No. 
Osteoarthritis 3
Rheumatoid arthritis 2 
Psoriatic arthritis 1
Pseudo-gout 1 
Arthritis secondary to an inflammatory bowel disease 1 
Bunion 1
Palindromic rheumatism 1
IgM-RF positive arthritisa 1 
IgM-RF and anti-CCP negative, ANA positive arthritisa 1
Unspecified monoarthritis 24 
Total: 36
MTP1: first metatarsophalangeal; ANA: antinuclear antibody; IgM-RF: IgM rheumatoid factor; 
anti-CCP: anticyclc citrullinated peptide.
aCannot be classified as rheumatoid arthritis.
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The detection of monosodium urate crystals in synovial fluid
Introduction
The gold standard for diagnosing gout is the identification of monosodium urate (MSU) 
crystals in synovial fluid by polarization light microscopy (1, 2). Most often, however, 
gout is diagnosed without this preferable gold standard, e.g. at emergency departments 
or in primary care, where polarization light microscopy is not easily accessible. On 
contrary, polarization light microscopes could be more widely used if knowledge 
would dictate that immediate analysis of synovial fluid is no necessity. To allow delayed 
assessment of MSU crystals the presence of such crystals should be stable to withstand 
sample storage and transportation (3, 4). The aim of this study was to determine the 
ability to detect MSU crystals after long-term storage at different temperatures.
Methods
Synovial fluid aspirates of at least 1.2 ml (baseline) of 10 patients were collected at the 
rheumatology department of Rijnstate Hospital, The Netherlands, and were analyzed 
by experienced synovial fluid assessors (LK and MJ) for the presence of MSU crystals 
with polarization light microscopy. Every aspirate with MSU crystals present at baseline 
was divided over 30 cuvets of at least 40 µl each. 10 cuvets were stored at -20°C, 4°C 
and room temperature, respectively. No anticoagulant or preservative was added. All 
samples were re-analyzed by the same assessors for the presence of MSU crystals pseudo-
randomly at several time-points until week 24. 
Results
Figure 1 shows that detection of MSU crystals was still possible in the majority of 
synovial fluid samples, even after 24 weeks of storage. The total mean percentages of 
samples with re-identified MSU crystals present were 87, 69, and 89% in the -20°C, 
4°C, and 20°C groups, respectively. The number of evaporated samples was the largest 
in the 20°C group. The presence of MSU crystals upon repetitive assessments over time 
was variable, which might be due to intra- and interobserver variability, and difference 
in the concentration of MSU crystals per sample. 
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Discussion
Our results are partially in accordance with the literature. In a systematic review of 
Graf et al., 5 studies (3-7) were analyzed concerning storage in synovial fluid of gout 
patients (8). MSU crystals remained stable in synovial fluid stored at room temperature 
for 24-72 hours (4, 5, 9). After this time period the amount of MSU crystals decreased. 
Storage at 4°C slowed this process, and after 8 weeks in all patients MSU crystals could 
be identified (4). We did not study the amount of MSU crystals. However, our results 
did not show that more MSU crystals were re-identified after storage at 4°C compared 
to storage at 20°C. Our results agree with the literature that anticoagulation was not 
required (3). And we show that not only dried cytospin preparations allowed long-term 
storage and delayed analysis (7), but also synovial fluid stored without any specific 
conservation process. 
Conclusion
Altogether, this study underscores that synovial aspirates can be stored for delayed 
analysis with polarization light microscopy to detect MSU crystals. This could increase 
the availability of synovial fluid analysis to improve the validity of the diagnosis of 
gout at emergency departments and in primary care, when the facilities are not easily 
accessible.
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Abstract
Objectives
The gold standard for diagnosing gout is the identification of monosodium urate (MSU) 
crystals in joint fluid. In secondary care the facilities or expertise to analyze joint fluid 
are not always available, and gout is diagnosed clinically. To improve the predictive 
value of the clinical diagnosis of gout in secondary care, a diagnostic rule developed in 
primary care could be helpful. The aim of this study was to validate this diagnostic rule 
in a secondary care population with the gold standard as reference test. 
Methods
390 patients with monoarthritis were included. The variables of the diagnostic rule 
(male sex, previous arthritis attack, onset <1 day, joint redness, involvement of the first 
metatarsophalangeal joint, hypertension or one or more cardiovascular disease, and 
serum uric acid >5.88 mg/dl) were collected and scored. The affected joint was aspirated 
and joint fluid was analyzed for the presence of MSU crystals.
Results
In 219 patients (56%) MSU crystals were found. The positive predictive value of a score 
of ≥8 points was 0.87, the negative predictive value of a score of ≤4 points was 0.95. 
The area under the receiver operator characteristic curve for the diagnostic rule was 
0.86 (95% confidence interval 0.82-0.89). The Hosmer-Lemeshows’ goodness-of-fit 
test showed that the difference between the expected and the observed probability was 
non-significant (P=0.64), indicating good agreement. 
Conclusions 
An easy-to-use diagnostic rule for gout developed in primary care shows a good 
performance in secondary care and improves the predictive value of the clinical diagnosis 
of gout when joint fluid analysis is not available. 
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Introduction
Gout is a common problem that affects 1.4% of the population (1). The gold standard 
for diagnosing gout is the identification of monosodium urate (MSU) crystals in joint 
fluid by polarization microscopy (2, 3). Although this is the gold standard, in some 
patients joint fluid analysis is not performed. Joint fluid analysis requires skills in 
arthrocentesis, the availability of polarization microscopy and familiarity with the use of 
this microscope. In primary care (4), but also in secondary care at emergency or other 
non-rheumatology departments, the facilities or expertise to analyze joint fluid are not 
always available. Even rheumatologists often lack these facilities or expertise (5, 6). Then 
gout is diagnosed based on clinical signs and symptoms only. 
However, it has been shown that the validity of the clinical diagnosis of gout in primary 
care is limited (positive predictive value (PPV) 0.64 and negative predictive value (NPV) 
0.87) (7). To improve the predictive value of the clinical diagnosis of gout in primary 
care, a diagnostic rule (gout calculator) was developed (7). This diagnostic rule includes 
scores for the following seven variables: male sex, previous patient-reported arthritis 
attack, onset within 1 day, joint redness, involvement of the first metatarsophalangeal 
(MTP1) joint, hypertension or one or more cardiovascular diseases and serum uric 
acid exceeding 5.88 mg/dl (equal to 0.35 mmol/l). The total score of the variables of 
4 or fewer of these variables ruled out gout in 97%. Gout was confirmed by MSU 
crystal identification in 80% of the patients with a score of 8 or higher. A midrange 
score (a score between 4 and 8), leaving uncertainty about the diagnosis, was found in 
approximately 15% of the patients and the authors suggested that joint fluid analysis 
be performed for this group (7). A valid diagnosis is of clinical importance in providing 
the right therapeutic measures, correct information to the patient and correct estimation 
of the prognosis (especially with respect to cardiovascular risks and morbidity(8-12)).
The easy-to-use diagnostic rule without joint fluid analysis developed in a primary care 
population showed a clinically highly relevant validity (7). If the same validity could be 
shown in secondary care patients, the diagnostic rule may also have clinical relevance for 
this population as well. The objective of this study was to validate this diagnostic rule for 
patients with monoarthritis diagnosed at a rheumatology department (secondary care). 
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Methods
Patient selection
This was a prospective diagnostic validation study performed from 1 January 2011 until 
8 May 2013 in the eastern part of the Netherlands. Adult patients who were diagnosed 
in our regional gout research centre (Department of Rheumatology, Rijnstate Hospital, 
Arnhem) with signs and symptoms of monoarthritis at their first visit, who conceivably 
could have gout, were included upon referral. These patients were considered as persons 
with a prior probability of acute gout arthritis (the research source population). For this 
reason patients known with previously MSU crystal-proven gout were not included. 
Patients were referred by general practitioners, emergency care physicians, cardiologists, 
internists, orthopedic surgeons or other secondary care physicians. According to 
the nature of this study (observing anonymously regular secondary care diagnostic 
interventions), and the Dutch law on performing medical research on humans (Medical 
Research Involving Human Subjects Act (WMO)), ethics committee approval was not 
required.
Baseline assessment
Patients were examined by physicians at the research centre (LK and MJ, and in a few 
patients substituted by a colleague rheumatologist). Data for all seven variables of the 
diagnostic rule were collected. The seven variables are male sex (score 2 points), previous 
patient-reported arthritis attack (score 2 points), onset within 1 day (score 0.5 points), joint 
redness (score 1 point), involvement of the MTP1 joint (score 2.5 points), hypertension or 
one or more cardiovascular diseases (angina pectoris, myocardial infarction, heart failure, 
cerebrovascular accident, transient ischaemic attack, or peripheral vascular disease) (score 
1.5 points), and serum uric acid exceeding 5.88 mg/dl (equal to 0.35 mmol/l) (score 
3.5 points) (7). The affected joint was aspirated and the joint fluid was analyzed with 
a polarization microscope for the presence of MSU crystals. When no joint fluid could 
be collected during arthrocentesis the patient was classified as having non-gout. When 
MSU crystals could not be identified, additional clinical and laboratory evaluations were 
performed to diagnose or exclude other forms of arthritis, including the identification of 
other joint fluid crystals, assessment of IgM rheumatoid factor and anticyclic citrullinated 
peptide antibody, radiographic evaluation, and, on indication, assessment of antinuclear 
antibody, antistreptolysin titer, anti-DNase B, or Borrelia IgM- and IgG-antibodies. 
Should there be a definite diagnosis fulfilling the accepted criteria of rheumatic diseases 
other than gout, the follow-up period was stopped. 
Finally, for each patient the score of the diagnostic rule was calculated after the follow-
up period. The physicians who performed the joint fluid analysis and who collected the 
variables of the diagnostic rule were blinded for the score.
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Follow-up
In the case of unspecified arthritis, the patient was followed up at the regional gout 
research centre until July 31, 2013, and was re-evaluated, including joint fluid analysis 
for the presence of MSU crystals, if a new episode of any arthritis occurred. If MSU 
crystals were identified during the follow-up period, the patient was retrospectively 
classified as already having had gout at the baseline assessment. The initial negative result 
for gout of the joint fluid analysis was then changed to a positive result.
Statistical analysis
Differences in the seven variables of the diagnostic rule between the gout and non-gout 
group at baseline were analyzed using the chi-squared test. The score of the diagnostic 
rule was calculated for every patient, and the mean scores of the group of patients with 
and without gout were compared using the Mann-Whitney U test.
A gout diagnosis according to the diagnostic rule was considered as the index test, 
with the identification of MSU crystals as the reference test. The performance of 
the diagnostic rule was evaluated by assessing the PPV, NPV, area under the receiver 
operator characteristics (ROC) curve, fit according to Hosmer-Lemeshow goodness-of-
fit test, and a calibration plot. The PPV (the number of patients with a positive index 
and reference test as a proportion of all patients with a positive index test) and NPV 
(the number of patients with a negative index and reference test as a proportion of all 
patients with a negative index test) were calculated for the three original cut-off scores 
using 2 x 3 tables.
Missing data were handled by multiple imputation analysis with five imputed data sets. 
All statistical tests were performed using PASW Statistics 18 (SPSS, Chicago, IL, USA).
Results
444 patients with signs and symptoms of monoarthritis were examined. 54 patients 
(12%) were excluded because arthrocentesis was not performed. The completeness of 
baseline data of the 390 included patients varied between 91% for serum uric acid >5.88 
mg/dl and 100% for sex and MTP1 involvement.
The mean age of the included patients was 61.0 years (standard deviation (SD) 14.0), 
and 274 (70%) of them were male. The affected joints were MTP1 (29%), knee (26%), 
ankle (17%), wrist (10%), elbow (4%), first interphalangeal joint of the foot (4%), 
proximal interphalangeal joint of the hand (3%), and other joints (7%). At baseline, 
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MSU crystals were identified in 49% (191 of 390 patients). During follow-up, MSU 
crystals were found in joint fluid during a recurrent arthritis in an additional 28 patients, 
resulting in 56% (219 of 390 patients) who were classified as having gout. 22% (86 of 
390 patients) fulfilled the criteria for other rheumatic diseases and 22% (85 of 390 
patients) had unspecified arthritis. Table 1 shows the variables of the diagnostic rule in 
the gout and the non-gout groups. 
Table 1. The seven variables of the diagnostic rule in patients with and without gout.
Variables of the diagnostic rule Gout 
(n=219)
Non-gout
(n=171)
n= No. (%) n=  No. (%) P value
Male sex 219 173 (79) 171 101 (59) 0.000
Previous patient-reported arthritis attack 217 176 (81) 168 53 (32) 0.000
Onset within 1 day 211 175 (83) 154 104 (68) 0.001
Joint redness 215 184 (86) 154 80 (52) 0.000
MTP1 involvementa 219 84 (38) 171 23 (14) 0.000
Hypertension or 1 or more cardiovascular diseasesb 219 161 (74) 171 80 (47) 0.000
Serum uric acid >5.88 mg/dlc 207 197 (95) 148 71 (48) 0.000
aMTP1 = first metatarsophalangeal joint
bAngina pectoris, myocardial infarction, heart failure, cerebrovascular accident, transient ischemic attack, or peripheral 
vascular disease
cA serum uric acid level of 5.88 mg/dl is equal to 0.35 mmol/l
The mean scores of the diagnostic rule were 8.6 (SD 2.1) and 5.2 (SD 2.5) (P<0.001) in 
the gout and the non-gout groups, respectively, with median scores of 8.5 (interquartile 
range (IQR) 7.1-10.5) and 5.1 (IQR 3.5-7.0). The area under the ROC curve for the 
diagnostic rule was 0.86 (95% confidence interval (CI) 0.82-0.89) (figure 1). The 
Hosmer-Lemeshow goodness-of-fit test showed that the difference between the expected 
and the observed probability was non-significant (P=0.64), indicating a good fit. Figure 
2 shows the calibration plot of the diagnostic rule. The triangles show the observed and 
the expected probabilities for having gout per decile of the predicted score. The triangles 
appear close to the line of identity, pointing to good fit and no systematic under- or 
overestimation. The PPV for a score of ≥8 points was 0.87 and the NPV for a score of 
≤4 points was 0.95.
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Figure 1. Area under the receiver operating characteristic (ROC) curve for the diagnostic rule. 
 
 
 
Figure 2. Calibration plot of the diagnostic rule. Every triangle is a decile of the score of the diagnostic rule (expected 
probability) plotted against the proportion of patients with presence of monosodium urate (MSU) crystals in that decile 
(observed probability).
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Discussion
According to the results of this study, the diagnostic rule for diagnosing gout without joint 
fl uid analysis, which was developed and validated in primary care, appeared to be valid in a 
secondary care population of monoarthritis patients as well. Th e diagnostic rule discriminated 
well between patients with and without MSU crystals in their joint fl uid, according to the 
area under the ROC curve. Moreover, the predicted probability for presence of MSU crystals 
agreed well throughout the range of the score with the observed probability of MSU crystals 
being present. It is an easy-to-use tool for practitioners that has now proved to be a valid 
instrument for diagnosing gout in primary and secondary care. It helps practitioners to select 
patients with high or low probability of gout among patients with a monoarthritis when 
joint fl uid analysis is not possible or available. By using the diagnostic rule, the PPV of the 
clinical diagnosis may improve from 0.64 to 0.87 and the NPV from 0.87 to 0.95 (7).
Th e study in primary care patients in which the diagnostic rule was developed showed 
an area under the ROC curve of 0.85 (95% CI 0.81-0.90) (7). Th e PPV for a score of 
≥8 points was 0.83 and the NPV for a score of ≤4 points was 0.98. Our validation study 
showed similar results. 
 
 
TOTAL SCORE 
PATIENT WITH MONOARTRHITIS  
Male sex:         2 points 
Prev ious  pa t ient-reported a rthri ti s  attack:     2 points 
Onset  with in 1 day:       0.5 points 
Joint  redness:         1 point 
Involvement of  the f i rs t MTP joint:     2.5 points 
Hypertens ion or ≥1 card iovascula r di sea ses* :    1.5 points 
Serum uric  acid >5.88 mg/dl**:      3.5 points 
≤4 points  
- Non-gout in 95% 
- Consider a different 
diagnosis, such as CPPD 
arthritis, reactive arthritis, 
septic arthritis, rheumatoid 
arthritis, osteoarthritis, or 
psoriatic arthritis  
 >4 and <8 points  
- Uncertain diagnosis 
- Perform joint fluid aspiration 
and analysis with polarization 
microscopy for the presence of 
crystals; if not possible or 
available, then extensive follow-
up of the patient 
 
≥8 points  
- Gout in 87% 
- Manage the patient as 
having gout, including care 
for cardiovascular risks 
Figure 3. Th e use of the diagnostic rule in clinical practice.
*   Angina pectoris, myocardial infarction, heart failure, cerebrovascular accident, transient ischemic attack, 
or peripheral vascular disease
** A serum uric acid level of 5.88 mg/dl is equal to 0.35 mmol/l
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In clinical practice the diagnostic rule can be used in patients with monoarthritis (figure 
3). When the rule indicates a low probability of gout (a score ≤4), the practitioner should 
consider a different diagnosis than gout, such as calcium pyrophosphate dihydrate arthritis, 
reactive arthritis, septic arthritis, rheumatoid arthritis, osteoarthritis, or psoriatic arthritis. 
When it indicates a high probability (a score  ≥8), the practitioner can consider that the 
monoarthritis is caused by gout, implying the specific management options for this disease 
including the evaluation of cardiovascular risk factors (13). When there is uncertainty about 
the diagnosis (a score between 4 and 8) should (still) be referred for joint fluid analysis. If 
joint fluid analysis is not possible or available, patients should be followed extensively for 
recurrent (gout) attacks or the occurrence of other specific rheumatic diseases. At all scores 
clinical re-evaluation of the patient is advisable in the case of a recurrent arthritis, because 
there always remains a risk of missing other important rheumatic diagnoses when patients 
are false-positively classified as gout by the diagnostic rule. 
If MSU crystals were identified during the follow-up period, the patient was 
retrospectively classified as already having had gout at the baseline assessment. On the 
one hand, the possibility remains that the initial arthritis attack was caused by a mono-
articular rheumatic disease other than gout, which can be expected to be rare. On the 
other hand, the probability that the initial flare was also caused by gout when MSU 
crystals are found in the recurrent flare is much higher, which was underscored by the 
finding that the same joint was affected at baseline and at follow-up arthrocentesis in 17 
of the 28 patients (61%; results not shown). 
When no joint fluid was collected during arthrocentesis (inadequate reference test) we 
have classified these patients (n=12) as non-gout, because in that case no MSU crystals 
could be identified. A different option would have been to exclude these patients from 
analysis. However, although not excluding could bias the performance of the rule, we do 
not expect a substantial change; a second arthrocentesis was successful during follow-up 
in 5 of 12 patients (results not shown) in which no joint fluid could be collected during 
arthrocentesis at baseline, leaving 7 patients without an adequate reference test.
The American College of Rheumatology criteria for classifying patients with gout were 
compared to the gold standard and they showed limited validity in two studies: a PPV of 
0.66-0.80 and a NPV of 0.65-0.82 (14, 15). The Chronic Gout Diagnosis (CGD) criteria 
developed for patients with chronic gout (16) compared with a clinical diagnosis of gout 
by a rheumatologist as reference test showed a PPV of 0.95 and a NPV of 0.98. There was 
a good correlation between the CGD criteria and the diagnostic rule (r=0.95; P=<0.001) 
(17). However, the controls were patients with a form of arthritis not mimicking gout 
and thus were not representative for the population of patients who are normally referred 
to secondary care and conceivably could have gout. The diagnostic value of the CGD 
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criteria could therefore be overrated. The diagnostic rule has shown a good performance in 
distinguishing between acute gout arthritis and septic arthritis (18).
A strength of our diagnostic study is the prospective design with a long follow-up period 
in which patients with unspecified arthritis were re-evaluated in case of any new arthritis. 
Not excluding patients with unspecified arthritis is consistent with clinical practice in 
which unspecified monoarthritis is prevalent.
A possible limitation is that the observer of the joint fluid, the assessor of the reference 
test, was not fully blinded for the clinical data used for scoring of the index test. However, 
there was blindness for the weights of the separate scores (from 0.5 to 3.5) and the sum 
total for the final score of the diagnostic rule, because both were calculated after the 
follow-up period. A second limitation is that MSU crystals might have been missed 
during joint fluid analysis, thereby patients falsely classifying as non-gout. However, 
besides the fact of a long follow-up of those of our patients with a negative joint fluid 
analysis, the sensitivity of crystal detection is 0.96 with a specificity of 0.87 in trained 
observers without previous experience in joint fluid analysis. The sensitivity of MSU 
crystal identification is 0.95 with a specificity 0.97 (19). Our study was performed 
in a research centre for gout with experienced joint fluid researchers. This makes the 
missing of MSU crystals less likely. A third limitation might be that 54 patients eligible 
for inclusion were excluded because arthrocentesis was not performed. However, we 
think that the exclusion of these patients did not bias our results substantially, as the 
patients included appeared to be highly representative of secondary care patients with 
monoarthritis, who conceivably could have gout. A fourth limitation might be that the 
diagnostic rule was developed and validated in patients with monoarthritis, who are, 
after excluding patients with oligo- or polyarthritis, not fully representative for patients 
with gout in the secondary care population. However, we feel confident that the rule 
will also work in patients with oligo- or polyarthritis suspected for gout, because of the 
strength of its performance in patients with monoarthritis. The diagnostic rule has been 
developed and now validated for the primary and secondary population in the eastern 
part of the Netherlands, which might affect its validity in other populations. Validation 
of the diagnostic rule in other countries in primary as well as secondary care would be 
welcome to determine whether the diagnostic performance remains robust. 
In conclusion, a diagnostic rule for diagnosing gout without joint fluid analysis in 
patients with monoarthritis, which was developed in a primary care population, has 
a good performance in a secondary care population. This easy-to-use rule helps to 
improve the predictive value of the clinical diagnosis of gout when joint fluid analysis is 
not possible or available. 
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Sir, we are grateful for the comments of Andrés et al. (1) on our article (2). They 
recommend that gout be diagnosed based on the identification of monosodium urate 
crystals with polarization light microscopy. Their main concerns are about applying a 
decision rule while there is a gold standard to diagnose gout. We endorse this ultimate 
goal, but to achieve this goal, many hurdles need to be overcome.
Gout is a potentially disabling but treatable rheumatological disorder with a high 
prevalence and incidence and important cardiovascular comorbidities. It is one of the 
few rheumatological diseases which can be diagnosed using a generally accepted gold 
standard. However, as Andrés et al. (1) state, gout diagnosis is still far from optimal by 
either general physicians or even rheumatologists or other secondary care physicians. In 
primary care, only in 3% of the patients is gout diagnosed by crystal identification, and 
fewer than 10% of all gout patients are referred to rheumatology departments (3). To the 
best of our knowledge, it is unknown how many rheumatological practices have access to 
polarization light microscopy and how often gout is diagnosed by crystal identification 
in non-primary care settings. In most published studies on gout, the diagnosis is 
established on paradigmatic clinical features and, unfortunately, crystal identification 
is often lacking. Therefore, until now, the majority of gout patients in primary and 
secondary care and in research settings are still diagnosed by clinical features. Since 
patients deserve the best valid method of gout diagnosis by their physicians, we propose 
a decision rule developed and validated in primary care that has shown comparably 
good performance in a secondary care setting. 
We agree with Andrés et al. (1) that clinical recognition relies on the clinical skills 
of the diagnosing physician to interpret the clinical features. However, the clinical 
recognition of general practitioners, who diagnose most gout patients, appears to have 
limitations in patients with a monoarthritis (4), and even in patients with a typical 
first metatarsophalangeal joint arthritis (podagra) (5). One might expect that clinical 
recognition of this rheumatic disease by rheumatologists is better. By using the diagnostic 
rule, clinical recognition did improve, as reflected in an increase in the positive and 
negative predictive values from 0.64 to 0.87 and from 0.87 to 0.95 respectively (4).
Of course, there is always the risk of reduced detection of those patients with fewer 
typical clinical features when applying this diagnostic rule. But we respectfully disagree 
with Andrés et al. (1) that the rule contributes to this risk, as it has cut-off points for 
excluding (a score ≤4) and including gout (a score ≥8), leaving an intermediate range. 
Expecting that less typical patients might have an intermediate score, we have formulated 
advice for the physician as to what to do with them, including referral for a diagnostic 
joint aspiration or possibly extensive follow-up.
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Because the diagnostic rule was developed in primary care (4), we wanted to test its 
validity in a secondary care population to be sure that the rule could also be applied 
in a different setting than for which it was built. The rule showed comparably good 
performance in a secondary care setting. Even in research conditions it appears to be 
an effective diagnostic tool for differentiating between gout and septic arthritis in a 
secondary care setting (6), and for testing the diagnostic performance of gout imaging 
in a tertiary care setting (7).
Compared with current daily practice, the diagnostic rule might improve the diagnostic 
evaluation of gout patients, leading to more disease-specific treatment, including care for 
comorbidities. At this time, in primary care it is impractical of impossible to diagnose 
each gout case after joint fluid analysis; it would involve an enormous workload, costs 
and patient inconvenience, as 90% instead of 10% of gout patients would be referred 
to hospitals with polarization light microscopy facilities. Nevertheless, we agree with 
Andrés et al. (1) that crystal identification remains the ultimate goal in diagnosing all 
gout patients, at least in secondary and tertiary care. In order to reach this goal we 
have to evaluate the need for rheumatologists to perform crystal identification properly. 
Continuous education, accreditation, validation with test panels and quality control 
of crystal identification skills are needed. Meanwhile, we offer physicians a validated 
diagnostic tool for diagnosing gout with a small uncertainty for a minority of the 
patients.
4a
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Chapter 5
Gout is a chronic infl ammatory disease in which high levels of 
interleukin 8 (CXCL8), myeloid-related protein 8/myeloid-
related protein 14 complex, and an altered proteome are 
associated with diabetes mellitus and cardiovascular disease
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Abstract 
Objective
The frequent association with metabolic syndrome and cardiovascular disease (CVD) 
suggests that it has a systemic component. Our objective was to study whether circulating 
proinflammatory cytokines are associated with comorbidities in gout patients.
Methods
We studied 330 gout patients from 3 independent cohorts and compared them with 
144 healthy individuals and 276 disease controls. We measured circulating levels of 
interleukin 8 (IL8)/CXCL8, IL1β, IL6, IL10, IL12, and tumor necrosis factor, after 
which we performed proteome-wide analysis in a selection of samples to identify proteins 
that were possibly prognostic for the development of comorbidities. Replication analysis 
was performed specifically for myeloid-related protein 8 (MRP8)/MRP14 complex.
Results
Compared to healthy controls and disease control patients, patients with gouty arthritis 
(n=48) had significantly higher mean levels of CXCL8 (P<0.001), while other cytokines 
were almost undetectable. Similarly, patients with intercritical gout showed high levels 
of CXCL8. CXCL8 was independently associated with diabetes mellitus in patients 
with intercritical gout (P<0.0001). Proteome-wide analysis in gouty arthritis (n=18) and 
intercritical gout (n=39) revealed MRP8 and MRP14 as the proteins with the greatest 
differential expression between low and high levels of CXCL8 and also showed a positive 
correlation of MRP8/MRP14 complex with CXCL8 levels (R² 0.49, P<0.001). These 
findings were replicated in an independent cohort. The proteome of gout patients with 
high levels of CXCL8 was associated with diabetes mellitus (odds ratio (OR) 16.5, 95% 
confidence interval (CI) 2.8-96.6) and CVD (OR 3.9, 95% CI 1.0-15.3). 
Conclusion
Circulating levels of CXCL8 are increased during both the acute and intercritical phases 
of gout, and they coincide with a specific circulating proteome that is associated with 
risk of diabetes mellitus and CVD. Further research focused on the roles of CXCL8 and 
MRP8/14 complex in patients with gout is warranted.
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Introduction 
Gouty arthritis affects 1-4% of the adult population in developed countries, where it is 
the most common arthritis in men (1, 2). Gout is a disorder of the purine metabolism 
that culminates in hyperuricemia and deposition of monosodium urate (MSU) crystals. 
Accumulating evidence suggests that the worldwide prevalence of gout is increasing, 
potentially attributable to factors including alcohol and sugar-sweetened beverage 
consumption, a purine-rich diet, and increased longevity (3). The association with 
widespread urate deposition (tophi) (4, 5), renal disease (6), metabolic syndrome 
(7), and an increased risk of cardiovascular disease (CVD) (7-13) suggests that gout 
is a systemic condition rather than a localized joint problem. An unmet need in the 
treatment of gout is the availability of biomarkers that would identify those patients at 
risk to develop these comorbidities. 
Although various studies describe the presence of local inflammatory mediators in 
the synovial fluid during gout attacks, to the best of our knowledge similar attempts 
to investigate the presence of systemic markers of inflammation, either during gouty 
arthritis or in the intercritical phase, are lacking (14-16). We studied the presence of these 
markers by analysing a selected group of proinflammatory cytokines and the circulating 
proteome in blood from patients with gouty arthritis and those with intercritical gout. 
In addition, we analyzed the possible association between circulating proteins with 
frequent coexistent CVD and/or diabetes mellitus. 
We observed that circulating levels of interleukin 8 (IL8)/CXCL8 are increased in a 
substantial portion of patients with gout. Using a non-hypothesis driven omics research 
approach, we demonstrated that high levels of CXCL8 coincide with a circulating 
proteome that is associated with increased risk of CVD and diabetes mellitus.
Patients and methods
This study included 330 gout patients from 3 independent gout patient cohorts, 
144 healthy individuals (129 from the Nijmegen Biomedical Study and 15 from the 
University Medical Centre Utrecht (17)), and disease controls comprising patients 
with rheumatoid arthritis (RA) (n=45), systemic sclerosis (SSc) (n=31), and dermatitis 
(n=200). The first gout cohort consisted of patients with gouty arthritis (n=48) (the 
Netherlands arthritis cohort) (figure 1). A second cohort of patients with intercritical 
gout from New Zealand (n=169) (the New Zealand intercritical gout cohort) was used 
for replication. For replication of the results for myeloid-related protein 8 (MRP8)/
MRP14 complex, a third cohort of patients with intercritical gout from The Netherlands 
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(n=113) (the Netherlands intercritical cohort) was used. All individuals were selected for 
age and sex, and local ethics approval had been granted. All data collection and analyses 
were performed from 2005 until 2013.
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Figure 1. Patient cohorts and analyses performed on these groups. See Patients and methods for descriptions of cohorts. 
NL-ARTHRITIS= Netherlands arthritis cohort; NZ-INTERCRITICAL= New Zealand intercritical cohort; IL1β= 
interleukin 1β; TNF= tumor necrosis factor; NL-INTERCRITICAL= Netherlands intercritical cohort; MRP8/14= 
myeloid-related protein 8 (MRP8)/MRP14 complex.
NL= The Netherlands; NZ= New Zealand
Detection of systemic markers of inflammation in gout patients
Proinflammatory cytokine levels of CXCL8, IL1β, IL6, IL10, IL12, and tumor 
necrosis factor (TNF) were measured in the circulation of gout patients. These levels 
were first investigated in patients with gouty arthritis since cytokine levels are thought 
to be highest during active disease. 48 patients with gouty arthritis were recruited 
by general practitioners in The Netherlands from 2005 until 2006 (the Netherlands 
arthritis cohort). After they had provided informed consent, patients were referred to 
the rheumatology department of the regional hospital to be included in an ongoing 
study (18). Patient characteristics were recorded. The diagnosis of gout was confirmed 
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by MSU crystal identification in synovial fluid. Cytokine levels were measured in the 
remainder of obtained for regular testing and frozen. 
To study whether these cytokine levels were similar during different disease states of gout, 
they were also measured in the circulation of patients with intercritical gout. A total of 
169 patients with intercritical gout were recruited from rheumatology outpatient clinics 
in New Zealand from 2008 until 2013 (the New Zealand intercritical gout cohort), 
and these patients were diagnosed as having gout according to the American College of 
Rheumatology preliminary criteria for the classification of the acute arthritis of primary 
gout (19). In most of these patients, MSU crystals were also identified in synovial fluid. 
All patients had previously had gout attacks. Patient characteristics were recorded, and 
blood samples were frozen. Recruitment of gout patients was approved by the New 
Zealand Multi-region Ethics Committee (MEC/05/10/130). All patients provided 
written informed consent. This cohort comprised patients of European Caucasian 
(n=106), Māori (n=25) and Pacific Islander (n=38) descent. Samples from all Māori 
and all Pacific Islander patients were measured for all cytokines. Because these samples 
and the samples of the Netherlands arthritis cohort showed high levels of CXCL8 but 
normal levels of the other cytokines, only 23 of the European Caucasian samples were 
measured for all cytokines. To reduce costs, the remainder 83 samples were analyzed for 
CXCL8 alone. 
Cytokines in the Netherlands arthritis cohort and in the Netherlands intercritical gout 
cohort were measured using a BD Cytometric Bead Array (CBA) kit (BD Biosciences), 
because this method had been used in the hospital (Rijnstate Hospital, Arnhem, The 
Netherlands) from which these patients had been referred. Capturing beads of known 
size and fluorescence were conjugated with a cytokine-specific antibody to bind cytokines 
in solution. A mixture of phycoerythrin (PE)-conjugated antibodies, used as detector 
reagent, provided a fluorescent signal in proportion to the amount of bead-bound 
cytokine. A series of 10 recombinant cytokine standards with known concentrations 
(ranging from 20 pg/ml to 5,000 pg/ml, plus a blank control) were used to measure 
cytokine levels in each experiment. Each individual standard curve for a given cytokine 
defines the minimum and maximum quantifiable levels using the BD CBA kit. By 
applying a 4-parameter curve fit option, values for sample intensities that fell outside 
the limits of the standard curve (<20 pg/ml or >5,000 pg/ml) could be extrapolated. 
After the flow cytometric data acquisition, FCAP Array software (Soft Flow) was used to 
extrapolate the cytokine concentrations from the PE-fluorescence intensities. Cytokines 
in the New Zealand intercritical cohort, in healthy individuals, and in disease controls 
were measured using well-known Luminex Assays. Cytokine levels are shown as mean ± 
standard deviation (SD). 
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To study whether circulating CXCL8 levels were associated with levels of other cytokines, 
the 86 New Zealand intercritical gout cohort patients from whom all cytokines were 
measured were arbitrarily stratified into groups of roughly equal size based on low, 
intermediate, and high levels of CXCL8. Levels of other cytokines were determined in 
these 3 groups to find correlations.
Proteomic analysis
To gain more insight into the proteins involved in systemic inflammation, we analyzed 
the proteome of CXCL8 (i.e. whether highly expressed proteins in patients with high 
CXCL8 levels were different from highly expressed proteins in patients with low 
CXLC8 levels). To enable us to find differences in the circulating proteome profile, 
we investigated the profile only in patients with the highest and the lowest CXCL8 
levels. The proteome profile was first investigated in a subgroup of the Netherlands 
arthritis cohort with the lowest (n=9) and the highest (n=9) CXCL8 levels. To validate 
the proteomics results the proteome profile was also investigated in a selected subgroup 
of the New Zealand intercritical cohort with the lowest (n=20) and the highest 
(n=19) CXCL8 levels. Proteomic analysis was performed using surface-enhanced laser 
desorption ionisation-time-of-flight mass spectrometry (SELDI-TOF-MS) technology 
(Ciphergen Biosystems) (for details, see ref (20)).
Statistical analysis
Association of systemic markers of inflammation (CXCL8 levels) with comorbidities 
The association of CXCL8 levels with clinical characteristics (age at disease onset, 
number of gout attacks, body mass index (BMI), systolic and diastolic blood pressure, 
serum creatinine levels, and serum uric acid levels) and comorbidities (diabetes mellitus, 
CVD, hypercholesterolemia, tophi, and chronic kidney disease (defined as a glomerular 
filtration rate <60 ml/minute)) was tested in the New Zealand intercritical cohort. 
CVD was defined as transient ischemic attack, cerebrovascular accident, myocardial 
infarction, peripheral vascular disease, heart rhythm disorder, angina pectoris, and/
or heart failure. As shown in Results, CXCL8 levels turned out to be associated only 
with the comorbidity of diabetes mellitus. Therefore, we further analyzed whether high 
CXCL8 levels were an independent risk factor for diabetes mellitus in gout patients. 
First, possible confounders for CXCL8 in the relationship with diabetes mellitus were 
evaluated. Variables which could be possible confounders for this association were 
selected based on the literature. After univariate linear regression, variables with β 
coefficient ≤0.2 were considered possible confounders. Logistic regression was performed 
by adding possible confounders by forward selection. When the β coefficient changed 
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>10%, the variable was considered a confounder. The confounder was then kept in the 
multivariate logistic regression model. If the β coefficient was significant for CXCL8 
(P<0.05) in the multivariate model after correction for confounders, then CXCL8 was 
considered independently associated with diabetes mellitus. Next, we tested CXCL8 as 
an independent predictor of diabetes mellitus using CXCL8 as a continuous variable.
Analysis of proteome and association with comorbidities 
The measured proteins were hierarchically clustered based on Pearson correlation 
coefficients. Hierarchical clustering and statistical analysis was performed using 
GenePattern software (21). For comparisons a t-test was used, and adjusted P values 
were calculated using exhaustive permutation when possible, or 100,000-fold 
permutation when software limits were reached. The program TagIdent was used for the 
identification of candidate proteins corresponding to the mass/charge scores from the 
heat maps by performing a query on the molecular weight (±1%) of each protein (22). 
The scan in UniProtKB/Swiss-Prot (http://www.uniprot.org/uniprot/) was restricted 
by organism  name “homo sapiens” and the use of the keyword “secreted”, referring 
to the cellular component of the protein. Gene Ontology (http://geneontology.org) 
was performed on the predicted protein lists using the Functional Annotation tool of 
DAVID version 6.7 (23).
We further investigated MRP8/MRP14 complex, the protein with the greatest differential 
expression between patients with low CXCL8 levels and those with high CXCL8 levels, 
as shown in Results. To validate whether this protein was increased in gout, we wanted 
to specifically measure MRP8/MRP14 complex in the New Zealand intercritical cohort 
by using enzyme-linked immunosorbent assay (24-26). Unfortunately, these samples 
had become hemolytic. Therefore, MRP8/MRP14 complex was measured in a different 
cohort of 113 patients with MSU crystal-proven intercritical gout (the Netherlands 
intercritical gout cohort). These patients were included from 2011 until 2012 at 
the rheumatology department of a regional hospital in the Netherlands. All patients 
provided written informed consent for the freezing of blood samples. Levels of both 
MRP8/MRP14 complex and CXCL8 were measured in these samples. The correlation 
between levels of MRP8/MRP14 complex and levels of CXCL8 levels was calculated.
The association of comorbidities with the proteome of low and high levels of circulating 
CXCL8 was studied to identify proteins that could be used to predict which gout 
patients were at risk of developing comorbidities. The association of comorbidities with 
the proteome profile associated with low and high CXCL8 levels in gout patients was 
tested in the subgroup from the New Zealand intercritical gout cohort with the lowest 
(n=20) and the highest (n=19) CXCL8 levels. To analyze whether clustering on the 
basis of the proteome of low and high CXCL8 levels showed an association between 
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CXCL8 levels and the co-occurrence of diabetes mellitus and CVD, we calculated odds 
ratios (ORs) and 95% confidence intervals (CI). The OR for CVD was calculated after 
stratification for hypercholesterolemia and diabetes mellitus.
Results
Figure 1 shows the patients cohorts and controls and the analyses performed. Table 1 
shows the phenotypic characteristics of the gout patients.
Table 1. Phenotypic characteristics of the gout patients*
Netherlands  
arthritis cohort 
(n=48)
New Zealand 
intercritical cohort
(n=169)
Netherlands 
intercritical cohort
(n=113)
Age, years 57.3 ± 15.2 51.3 ± 14.8 65.1 ± 12.8
Disease duration, years NA 16.0 ± 12.8 NA
Male, % 87.5 87.3 83.2
Body mass index, kg/m² 28.9 ± 4.7 33.5 ± 8.1 29.3 ± 4.8
Tophi present, % 14.6 42.2 34.5
Serum uric acid, mmol/l 0.50 ± 0.1 0.57 ± 0.1 0.36 ± 0.14
C-reactive protein, mg/l 33.8 ± 56.2 NA 11.2 ± 18.2
Hypertension, % 56.3 56.4 70.8
Diabetes, % 8.3 22.1 17.7
Cardiovascular disease, %** 33.3 43.6 53.1
Hypercholesterolemia, % 29.2 46.6 43.4
Chronic kidney disease, %*** 25.0 37.4 37.2
Medication used, %
Diuretics 33.3 18.4 40.7
Steroids 4.2 59.6 4.4
NSAIDs 22.9 82.9 13.3
Allopurinol 2.1 87.7 64.6
Probenecid 0 10.0 0
Benzbromarone 0 NA 16.8
Febuxostat 0 NA 2.7
Colchicine 8.3 73.1 55.8
*Except where indicated otherwise, values are the mean ± SD. See Patients and methods for description of cohorts. NA= 
not applicable; BMI= body mass index; NSAIDs= nonsteroidal anti-inflammatory drugs.
**Defined as transient ischemic attack, cerebrovascular accident, myocardial infarction, peripheral vascular disease, heart 
rhythm disorder, angina pectoris, and/or heart failure.
***Defined as a glomerular filtration rate of <60 ml/minute.
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Figure 2. CXCL8 levels are highly increased in patients during gouty attacks and in the intercritical phase of gout. 
A. Shown are circulating levels of CXCL8, interleukin 1β (IL1β), IL6, IL10, IL12, and tumor necrosis factor (TNF) 
in patients with recent-onset gouty attack (n=48) in the Netherlands arthritis cohort. B. Extremely increased levels of 
CXCL8 were observed in patients with intercritical gout from New Zealand. This cohort comprised patients of European 
Caucasian (n=106), Māori (n=25) and those from Pacific Islander (n=38) descent. Only 23 of the European Caucasian 
samples were measured for all cytokines. The remaining 83 samples were analyzed for CXCL8 alone. Symbols represent 
individual patients; bars show the mean ± SD. See Patients and methods for the description of cohorts.
Systemic markers of inflammation in gout patients
Compared 144 healthy individuals (mean ± SD 47 ± 13 pg/ml) 45 RA patients (mean ± 
SD 38 ± 28 pg/ml), 31 SSc (mean ± SD 44 ± 51 pg/ml), and 200 patients with dermatitis 
(mean ± SD 44 ± 34 pg/ml), a remarkably high mean level of circulating CXCL8 was 
measured in the Netherlands arthritis cohort (mean ± SD 226 ± 574 pg/ml) (P <0.001). 
If we consider the upper cut-off value for normal to be the mean + 2 SD (<73 pg/ml), 
then 27% of patients in the Netherlands arthritis cohort and 51% of patients in the 
New Zealand intercritical cohort had greater-than-normal circulating levels of CXCL8. 
In contrast to levels of CXCL8, levels of IL1β, IL6, IL10, IL12 and TNF were almost 
undetectable (figure 2A). There was no association between circulating levels of CXCL8 
and markers of inflammation such as C-reactive protein or erythrocyte sedimentation 
rate. In the New Zealand intercritical cohort, similar high levels of CXCL8 were observed 
compared to the other inflammatory mediators (figure 2B), thus replicating previous 
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observations. Again, no differences in levels of CXCL8 or in levels of IL1β, IL6, IL10, 
IL12 or TNF were observed between the 3 different ethnic groups. 
Figure 3. High circulating levels of CXCL8 levels are associated with co-occurrence of diabetes mellitus in patients 
with intercritical gout. After stratification of patients with intercritical gout by low CXCL8 levels(<100 pg/ml; n=68), 
intermediate CXCL8 levels (100-500 pg/ml; n=42), and high CXCL8 levels (>500 pg/ml; n=59), high levels of CXCL8 
were found to be associated with the levels of circulating urate (A) and co-occurrence of diabetes mellitus (B). Symbols 
represent individual patients; bars show the mean ± SD. See Patients and methods for the description of cohorts.
Association of CXCL8 levels with comorbidities
In the New Zealand intercritical cohort, CXCL8 levels were significantly associated 
with a greater number of gout attacks (P<0.001) (data not shown) and with serum uric 
acid levels (P<0.001, figure 3A), while other clinical variables, such as age at disease 
onset, sex, BMI, presence of tophi, systolic and diastolic blood pressure, and serum 
creatinine levels, were not (data not shown). The frequency of diabetes mellitus, but not 
CVD, hypercholesterolemia or chronic kidney disease, was clearly associated with a high 
CXCL8 level (P<0.0001) (figure 3B). To investigate whether CXCL8 is an independent 
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risk factor for diabetes mellitus in gout, we performed multivariate modelling in which 
we first evaluated possible confounders for CXCL8 in the relationship with diabetes 
mellitus (supplementary table 1). Next we tested CXCL8 as an independent predictor 
for diabetes mellitus using CXCL8 levels as a continuous variable (supplementary table 
2). In these models, CXCL8 independently predicted the co-occurrence of diabetes 
mellitus in gout patients. 
Figure 4. A serum proteome-wide analysis of gout patients during a gouty attack identifies a unique protein profile 
associated with interleukin (IL) 8/CXCL8. Proteome-wide analysis using surface-enhanced laser desorption ionization-
time-of-flight mass spectrometry was performed on serum from patients with gout during a gouty attack (n=18). 
Stratification of patients by high CXCL8 levels (>100 pg/ml; n=9) and low CXCL8 levels (<10 pg/ml; n=9) revealed 
a highly distinct predicted protein profile. A. Proteins with low expression are shown in green, while proteins present 
in high concentrations are shown in red. B. Myelin-related protein (MRP) 8 and MRP14 were identified as the most 
differentially expressed proteins in patients with high CXCL8 levels and patients with low CXCL8 levels. Symbols 
represent individual patients; bars show the mean. C. After validation in a cohort of Dutch patients with intercritical 
gout (n=113), increased levels of MRP8/MRP14 complex were found to be closely correlated with increased levels of 
circulating CXCL8 (R2 0.49, P<0.001). See Patients and methods for description of cohorts.
84
Chapter 5
Proteomic analysis with SELDI-TOF-MS
We have previously used SELDI-TOF-MS successfully to identify proteins associated 
with diseases in a non-hypothesis-driven manner (20, 27). Given that increased 
circulating CXCL8 levels did not correlate with levels of cytokines such as IL1 and TNF, 
which had been expected to be high, we postulated that a non-hypothesis-driven omics 
research approach – by measuring the proteome - would provide most efficient insights 
into the possible components coinciding with highest circulating levels of CXCL8. 
SELDI-TOF-MS provides such an omics research tool measuring a wide spectrum of 
the proteome, which we chose to perform in 2 “extreme” subgroups - patients with 
lowest CXCL8 levels and patients with highest CXCL8 levels - an approach which is 
often applied in omics research. SELDI-TOF-MS expression profiles indeed revealed 
clearly distinct subsets of candidate proteins differentially expressed in the Netherlands 
arthritis cohort between 9 patients with low (<10 pg/ml) and 9 patients with high (>100 
pg/ml) CXCL8 levels (figure 4A). Totals of 574 and 1,028 candidate proteins had high 
expression in patients with low CXCL8 levels and patients with high CXCL8 levels, 
respectively, with most having a role in the regulation of innate and adaptive immune 
responses (supplementary table 3). The candidate proteins with the greatest differential 
expression between low and high CXCL8 levels were MRP8 (P<0.001) and MRP14 
(P<0;0001) (figure 4B). Measurement of MRP8/MRP14 complex in the Netherlands 
intercritical cohort demonstrated a positive correlation of MRP8/MRP14 complex 
with CXCL8 levels (R2 0.49, P<0.001) (figure 4C). Consistent with findings in the 
Netherlands arthritis cohort, the expression profiles from proteomic analysis in the New 
Zealand intercritical cohort also revealed distinct profiles in 20 patients with low (<100 
pg/ml) and 19 patients with high (>500 pg/ml) CXCL8 levels (P<0.002) (data not 
shown).
Association of the co-occurrence of diabetes mellitus with a specific proteome in 
patients with high levels of CXCL8
In the subgroup of the New Zealand intercritical cohort with low (n=20) and high 
(n=19) CXCL8 levels, we investigated whether the proteome associated with low and 
high circulating CXCL8 levels was related with co-occurrence of diabetes mellitus. After 
stratification for CXCL8 level, there was a clear association (OR 16.5, 95% CI 2.8-96.6; 
P<0.0001). The association was predicted by low expression of proteins between 4,565 
and 4,585 Daltons (vasoactive intestinal peptide and liver-expressed antimicrobial 
peptide 2) and between 58,995 and 60,392 Daltons (elastin), and by high expression of 
chemokines (CCL18, CCL20, CXCL4, and other inflammatory mediators) (figure 5). 
585
Gout is a chronic inflammatory disease
Common significant peak (Daltons) Higher in patients with Possible proteins 
4,565 - 4,585 Low IL8 COLI, LEAP2, PENK, VIP, PPAP 
58,995 - 60,392 Low IL8 ELN 
7,650 - 7,707 High IL8 IL8, CCL18, CCL20, CCL22, CCL3, CCL4, CCL5, CK094, CKLF, 
CL3L1, CXCL5, DB110, GROA, IGF1, ISK5, CXCL4, SG1D2, 
TOR2A 
12,692 - 12,698 High IL8 CCL26, CE064, CMGA, F19A1, FNDC5, GDF1, GHRL1, IL15, 
INHBB, INSL4, KLK8, LYNX1, NODAL, NRG4, PS1C2, RSPRY, 
SAA4, SG11B, TGFb, YQ032 
 
Figure 5. Unsupervised clustering identifies an interleukin (IL) 8/CXCL8-dependent proteome in patients during 
the intercritical phase of gout that is associated with co-occurrence of diabetes mellitus. In proteome-wide analysis of 
serum from New Zealand patients with intercritical gout (n=39), unsupervised clustering revealed that the CXCL8-
related proteome is associated with the co-occurrence of diabetes mellitus (odds ratio 16.5; 95% confidence interval 
2.8-96.6). Proteins with low expression are shown in green, while proteins present in high concentrations are shown 
in red. COLI= adenomatous polyposis coli; LEAP2= liver-expressed antimicrobial peptide 2; PENK= proenkephalin; 
VIP= vasoactive intestinal peptide; PPAP= glucan endo-1,3-β-glucosidase 10; ELN= elastin; CK094=chromosome 
11 open-reading frame 94; CKLF= chemokine-like factor; CL3L1= chemokine ligand 3-like 1; DB110= β-defensin 
110; GROA= melanoma growth-stimulating activity α; IGF1= insulin-like growth factor 1; ISK5= serine peptidase 
inhibitor, kazal type 5; SG1D2= secretoglobin, family 1d, member 2; TOR2-A= torsin family 2, member A; CE064= 
chromosome 5 open-reading frame 64; CMGA= chromogranin a; F19A1= family with sequence similarity 19, member 
a1; FNDC5= fibronectin type III domain–containing 5; GDF1= growth differentiation factor 1; GHRL1= grainyhead-
like 1 (Drosophila); INHBB= inhibin βB; INSL4= insulin-like 4 (placenta); KLK8= kallikrein-related peptidase 8; 
LYNX1= Ly-6/neurotoxin-like protein 1; NODAL= nodal growth differentiation factor; NRG4= neuregulin 4; PS1C2= 
psoriasis susceptibility 1 candidate 2; RSPRY= ring finger and SPRY domain–containing 1; SAA4= serum amyloid 
A4, constitutive; SG11B= sperm-associated antigen 11b; TGFb= transforming growth factor β; YQ032= putative 
uncharacterized protein FLJ46089. See Patients and Methods for descriptions of cohorts.
86
Chapter 5
Next we investigated in the same group of patients whether the CXCL8-associated 
proteome could also be used to identify those gout patients who have CVD after 
stratification for diabetes mellitus and hypercholesterolemia. Although the result was 
less clear compared to the presence of diabetes mellitus, co-occurrence of CVD could be 
linked to high levels of CXCL8 and its associated proteome (OR 3.9, 95% CI 1.0-15.3; 
P<0.001). Candidate proteins that displayed lowest expression in gout patients with high 
CXCL8 levels and CVD were chromogranin A, natriuretic peptide B and oncostatin 
M, while proteins with highest expression comprised thrombopoietin, CXCL7, apelin, 
CXCL4, renin, IL32 and complement factors (supplementary table 4). 
Discussion
We demonstrate for the first time that circulating CXCL8 levels are increased both in 
patients with the gouty phase of the disease and in patients with the intercritical phase, 
as compared to healthy donors as well as to patients with other inflammatory conditions, 
such as RA, SSc, and dermatitis. High circulating CXCL8 levels were associated with 
the co-occurrence of diabetes mellitus. Further investigation of the circulating proteome 
of patients with low CXCL8 levels an patients with high CXCL8 levels revealed distinct 
proteomes that were clearly associated with the presence of diabetes mellitus and CVD, 
both recently described to be clinically significant complications of gout (28, 29). The 
protein MRP8/MRP14 complex was found to be most closely associated with circulating 
CXCL8 levels. 
We found an association between CXCL8 levels and diabetes mellitus in gout patients; 
however, we did not detect an association between CXCL8 levels and CVD. Although 
many reasons could underlie this observation, we believe that it is due to the low 
number of gout patients having CVD without diabetes mellitus in our cohort. CXCL8 
is a prototypical chemokine of the CXC subfamily (30). Although all nucleated cells 
are potential sources of CXCL8, monocytes and macrophages are typically considered 
the main producers. However, accumulating evidence suggests the role of activated 
endothelial cells in circulating CXCL8 levels (30, 31) and a pivotal role for CXCL8 in 
CVD. For instance, high CXCL8 levels were observed in human atherosclerotic wall, 
but also in fibrous plaques (32). Macrophages especially, but practically all cells of the 
vascular wall, were demonstrated to be the source of CXCL8 in atherosclerotic plaques 
(33). In addition, many non-gout-focused studies showed a role for CXCL8 in predicting 
CVD. CXCL8 functions as an independent predictor for clinical outcome in patients 
with coronary artery disease (34) and for CVD in patients with end-stage renal disease 
(35). Finally, CXCL8 was found to be increased in diabetes mellitus and suggested to 
be a marker linking obesity with metabolic complications such as atherosclerosis and 
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diabetes mellitus (36, 37). Taken together, CXCL8 is clearly implicated in inflammatory 
processes that drive atherosclerosis and diabetes mellitus. 
Proteome-wide analysis identified MRP8/MRP14 complex, also known as S100A8/
A9, as a marker potentially associated with risk of CVD and diabetes mellitus in gout. 
MRP8/MRP14 complex was identified as a Toll-like receptor (TLR) 4 agonist (38). 
Increased levels of MRP8/MRP14 complex both during attacks of gout and during 
intercritical gout might provide a link between chronic inflammation and the risk of 
CVD and/or diabetes mellitus in gout patients. This is consistent with recent observations 
where MRP8/MRP14 complex was identified as a biomarker for mortality prediction 
in patients with heart failure (39), associated with systemic inflammation in stable 
coronary atherosclerosis (40), and involved with aberrant TLR-mediated inflammatory 
responses in humans with acute coronary syndrome (41). Similar to its association with 
CVD, MRP8/MRP14 complex is associated with hallmark features of diabetes mellitus: 
diabetic retinopathy and nephropathy (42). In addition to CXCL8 and MRP8/MRP14 
complex, we showed that the overall proteome profiles separated patients with CVD 
and/or diabetes mellitus from those without these comorbidities. 
Interestingly, markers expressed at low levels in patients CVD and high levels of CXCL8 
constitute a group of proteins normally designed as negative modulators of neuroendocrine 
and/or immune responses. For instance, chromogranin A is a precursor of vasostatin, 
pancreastatin, and parastatin. Reduced levels of vasostatin were recently associated with 
the presence and severity of coronary artery disease (43), and chromogranin A-knockout 
mice displayed hypertension, higher adipokine levels, and altered glucose homeostasis, 
further substantiating a crucial role in homeostatic control of inflammation and diabetes 
mellitus (44). Another example is oncostatin M, which has a proven major role in 
cardiac protection and repair (45). In contrast, various inflammatory mediators (IL32, 
CXCL7, CXCL4, thrombopoeitin, apelin) previously shown to have a direct effect role 
on immune activation and/or CVD were associated with CXCL8 levels (46). Those 
findings further substantiate the validity of our observations for potential clinical use in 
predicting which gout patients should be followed up more intensively for the presence 
of CVD and/or diabetes mellitus. 
Recently, several conceptual frameworks have been proposed to explain the pathogenesis 
of gout. Although the role for MSU crystals has long been unclear, it is generally 
well accepted that MSU crystals exert a direct proinflammatory effect, including the 
production of cytokines such as IL1β via engagement of the TLR family and the 
inflammasome (47, 48). More recently, neutrophil extracellular traps (NETs)(49), 
which trap and kill microbes to avoid spreading of potential pathogens, have also been 
linked to mediators causing sterile inflammation such as CXCL8 and TNF (50, 51). In 
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contrast to our knowledge of the mechanisms causing gouty arthritis, the relationship 
with associated chronic conditions is poorly understood. For instance, hyperuricemia 
itself has been associated to chronic renal dysfunction (10), hyperinsulinemia (10), 
hypertension (10), CVD (11), obesity, and diabetes (7). However, the mechanisms 
underpinning these associations are unknown, and there is continuing uncertainty as to 
whether circulating urate per se is detrimental. 
Although high levels of IL1β initiated by inflammasome activation might play an 
important role in gout attacks, high levels of CXCL8 do not support a direct role of the 
inflammasome, either in intercritical gout or in relation to comorbidity coinciding with 
gout. In fact, the observed increased levels of CXCL8 did not correlate with levels of 
IL1β; therefore, this finding by itself cannot be explained by inflammasome activation. 
An alternative explanation might be that the activation of macrophages due to TLR 
stimulation by MSU crystals is the initiating event. Subsequently, these macrophages 
activate the inflammasome but also produce high levels of CXCL8, which results in 
chemoattraction and activation of neutrophils in the affected joint, clinically reflected by 
a gouty arthritis. These activated neutrophils form NETs that in turn lead to activation 
of plasmacytoid dendritic cells, which have recently been shown to be able to produce 
high quantities of CXCL8 (20). 
In addition, the main constituent of activated neutrophils is MRP8/MRP14 complex, 
which is released in high quantities when these neutrophils perish, as is likely in gouty 
arthritis. Upon elimination of MSU crystals, inflammasome activation might resolve 
after a few days, which is reflected by improved clinical signs and symptoms. However, 
consistently high levels of CXCL8 and MRP8/MRP14 complex might directly activate 
synovial macrophages via TLR-dependent pathways, leading to endothelial dysfunction 
and possibly other yet-unidentified pathways that culminate in low-grade subclinical 
chronic inflammatory responses and promotion of CVD and/or diabetes mellitus. This 
concept would explain the clinical responses observed by therapies targeting IL1β in 
gout, and it also links MSU crystals with chronic low-grade inflammation and risk for 
CVD, diabetes mellitus, and other comorbidities so often observed. However, there is 
still no explanation for the existence of such a chronic self-perpetuation loop.
Taken together, we show that gout can be considered a chronic systemic inflammatory 
disease in which circulating CXCL8 levels are high irrespective of disease activity. Increased 
levels of CXCL8 in patients with gout were associated with diabetes mellitus, and the 
CXCL8-associated proteome was associated with co-occurrence of diabetes mellitus and 
CVD. Although the true clinical value of these biomarkers needs validation in a large 
prognostic cohort, our results suggest that they have a potential role in identifying those 
gout patients at risk for diabetes mellitus and CVD and requiring early intervention.
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Supplementary data
Supplementary table 1. Building of multivariate model.
Possible confounders Beta coefficient P value R2
LOG_IL1b levels 1.2 <0.001 0.405
LOG_IL6 levels 0.65 0.001 0.13
Urate levels 3.15 0.003 0.053
Sex -0.261 0.573 0.002
BMI -0.02 0.444 0.004
Age 0.01 0.42 0.004
Current Systolic blood pressure 0.005 0.56 0.002
Current Diastolic blood pressure -0.021 0.119 0.015
Age of first attack 0.004 0.655 0.001
Number of gout attacks 0.02 0.044 0.025
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Supplementary table 2. Multivariate model to analyze CXCL8 as an independent variable for the co-occurrence of 
diabetes in gout. 
Predictors Beta coefficient P value R2
Model 1 0.123
Log CXCL8 0.349 <0.0001
Model 2 0.15
Log CXCL8 0.427 0.018
Log IL1β -0.109 0.702
Model 3 0.167
Log CXCL8 0.407 0.025
Log IL1β 0.128 0.735
Log IL6 -.302 0.350
Model 4 0.177
Log CXCL8 0.462 0.012
Log IL1β -0.112 0.695
Urate level -2.353 0.211
Model 5 0.178
Log CXCL8 0.466 0.013
Log IL1β -0.11 0.702
Urate level -2.363 0.210
Number of gout attacks -0.002 0.899
Model 6 0.171
Log CXCL8 0.446 0.016
Log IL1β -0.094 0.744
Urate level -2.138 0.262
Current diastolic blood pressure 0.013 0.571
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Supplementary table 3. Protein candidates with high expression in patients with low and high CXCL8 during an acute 
gouty attack.
Gout patients with low CXCL8 Gout patients with high CXCL8
GO term N candidates P value GO term N candidates P value
Extracellular region 198 5.06-152 Extracellular region part 191 1.82-102
Extracellular region part 89 3.61-43 Growth factor activity 43 3.32-30
Extracellular space 67 9.12-32 Defense response 75 5.54-29
Endopeptidase inhibitor 
activity 18 9.04-10
Cytokine-cytokine receptor 
interaction 50 5.68-27
Defense response 33 1.36-09 Immune response 73 3.83-24
Peptidase inhibitor 
activity
18 2.20-09 Response to wounding 62 3.70-22
Complement and 
coagulation cascades 14 2.01-09 Peptidase activity 31 4.50-22
Acute inflammatory 
response
15 1.26-08 Inflammatory response 47 1.03-19
EGF-like region, 
conserved site
22 2.14-08 Serine-type endopeptidase 
activity
33 4.06-19
Response to wounding 29 3.16-08 Serine hydrolase activity 35 4.93-19
Endopeptidase activity 24 5.88-08 Chemokine activity 20 8.28-17
Peptidase activity 29 8.26-08 Carbohydrate binding 42 3.24-15
EGF-like, type 3 18 8.87-08 Pattern binding 28 1.55-13
Polysaccharide binding 28 1.55-13
Complement and 
coagulation cascades
21 3.66-13
Protein processing 24 2.71-12
Hormone activity 23 2.79-12
Protein maturation 24 1.90-11
Regulation of response to 
external stimulus 25 8.44-10
Extracellular matrix 42 6.61-10
Transforming growth factor 
beta, 
14 8.83-10
Positive regulation of 
response to stimulus
29 4.09-09
Glycosaminoglycan binding 22 6.69-09
Cell-cell signaling 46 1.24-08
TOTAL 574 1028
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Supplementary table 4. Candidate proteins (GO term) defining cardiovascular disease risk in intercritical gout patients 
displaying high CXCL8 levels.
Low expression in patients with high CXCL8 High expression in patients with high CXCL8
GO term N candidates P value GO term N candidates P value
Secreted proteins 40 5.06-40 Secreted proteins 127 8.18-124
Extracellular region 40 3.12-30 Extracellular region 129 4.04-99
Signal peptide 39 4.56-26 Signal peptide 117 9.07-70
Extracellular region part 19 4.76-09 Glycoprotein 82 1.18-24
Hormone activity 17 1.56-16
Cell-cell signaling 27 2.86-10
Growth factor activity 15 1.06-9
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A pilot study of CXCL8 levels in crystal proven gout patients 
during allopurinol treatment and their association 
with cardiovascular disease
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Abstract
Objectives
Gout is associated with cardiovascular diseases, and systemic inflammation has a role in 
this. CXCL8 (interleukin 8) levels were increased in synovial fluid of gout patients, and 
in serum in gout patients irrespective of their disease activity. We hypothesized that the 
well-known cardiovascular protective effects of allopurinol could be related to effects of 
this drug on CXCL8 levels.
Methods
Patients with a crystal proven gout diagnosis, who newly started allopurinol treatment, 
were included in this prospective cohort study. After evaluation at baseline for 
cardiovascular diseases, tophi, uric acid, CRP and CXCL8 serum levels, patients were 
followed for changes in uric acid and CXCL8 levels. A subgroup analysis was performed 
in 10 patients with the longest follow-up period and at least 4 assessments of serum uric 
acid and CXCL8. 
Results
Sixty patients were included, and patients known with cardiovascular diseases at baseline 
had significantly higher CXCL8 and uric acid levels (P<0.01). In the whole group, 
median CXCL8 levels had not decreased after a median (IQR) follow-up of 27 (12-44) 
weeks (P=0.66). In the subgroup analysis in 9 out of 10 patients, CXCL8 levels showed 
a slight decrease, sometimes after an initial increase after a median (IQR) follow-up of 
51 (45-60) weeks. 
Conclusions
This pilot study indicates that higher CXCL8 levels were associated cardiovascular 
diseases in gout patients. Short-term use of allopurinol does not decrease CXCL8 levels 
in gout patients, but longer use possibly does. Further studies are warranted to establish 
the potential mechanisms of treatment and effects on CXCL8 levels.
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Introduction
Gout is strongly associated with cardiovascular diseases (CVD) (1), and it is generally 
recommended to address cardiovascular comorbidity as part of the management of gout 
(2). Elucidation of the pathophysiological pathways of cardiovascular damage in gout 
patients is needed, to further optimize cardiovascular prevention programs. Systemic 
inflammation in chronic inflammatory diseases is a significant cause of atherosclerosis 
as it can lead to vessel wall inflammation. Also in gout patients, systemic inflammation 
seems present, although the exact mechanisms are unclear. CXCL8 (interleukin 8), 
a neutrophil chemotactic factor and pro-inflammatory cytokine, seems to play an 
interesting role in this as CXCL8 levels were increased in synovial fluid of gout patients 
(3), and high levels of CXCL8 were found in serum of gout patients irrespective of 
disease activity (4).
Xanthine oxidase inhibitor allopurinol has cardioprotective effects, but uricosurica do 
not (5, 6). Several studies suggest that this effect is the result of a direct or indirect 
reduction of vessel wall inflammation (7, 8). The effect of allopurinol on CXCL8 
levels in gout patients is unknown. We studied the hypothesis that the cardiovascular 
protective effects of allopurinol could be related to serum CXCL8 level lowering effects 
of this drug.
Methods
Patient selection
This prospective cohort study was performed in 2013-2014 at the Department of 
Rheumatology, Rijnstate Hospital, Arnhem, the Netherlands. Patients who visited the 
outpatient clinic in daily practice, who had a urate crystal-proven gout diagnosis, and 
who newly started with allopurinol treatment were recruited. Criteria for allopurinol 
treatment were frequently recurrent attacks (>3 per year), tophi, or gout specific 
radiographic changes (punched-out lesions). Exclusion criteria were the use of other 
uric acid (UA) lowering therapies, and contraindications for allopurinol treatment. To 
monitor their therapy regular blood tests were done. All patients were asked whether they 
would participate in medical research, including research on inflammatory parameters 
as CXCL8, by collecting extra serum samples during these regular blood tests which 
were stored at -20°C. 
The local ethical committee approved the collection of extra serum samples, and all 
included patients signed informed consent for that.
100
Chapter 6
Baseline and follow-up assessment
Patients were examined by physicians (L.K. and M.J., and a few by a colleague 
rheumatologist), at the outpatient clinic during regular daily practice. At baseline 
,clinical variables sex, age, presence of joint inflammation, tophi, and CVD at initiation 
of the allopurinol therapy were collected. CVD were defined as angina pectoris, 
myocardial infarction, heart failure, cerebrovascular accident, transient ischemic attack, 
and peripheral vascular disease. A serum sample was taken for measurement of UA, 
C-reactive protein (CRP), and glomerular filtration rate (GFR) levels, amongst others, 
as part of the regular blood tests. An extra serum sample was taken for storage at -20°C. 
The patient received a prescription for allopurinol treatment in a dosage adjusted for 
the renal function. After at least one month and further at coincidental moments, i.e. at 
outpatient visits as part of regular rheumatologic care, serum UA levels were assessed for 
monitoring treatment effect, and extra serum samples were taken for storage at -20°C. 
Allopurinol dosage was increased until the target UA (<0.36 mmol/l) was achieved. At 
a later time CXCL8 levels were measured in all stored serum samples measured by flow 
cytometry using BDTMCytometric Bead Array (CBA, BDBiosciences; USA). To test the 
intra-run variability, 3 samples were used as a control at every run. 
Statistical analysis
Descriptive statistics were used to summarize the clinical and biochemical variables at 
baseline as numbers (percentages), means (standard deviations (SD)), and/or medians 
(interquartile ranges (IQR)). Correlations between baseline CXCL8 levels and UA,CRP 
and GFR levels were analyzed by Spearman’s rho. Baseline data of patients with and 
without CVD were compared to evaluate whether CVD associated with clinical 
and biochemical variables. For comparison of sex, presence of joint inflammation, 
and presence of tophi, Fisher’s exact tests were used. To compare age the t-test was 
applied, and to compare UA, CRP, and CXCL8 levels the Mann-Whitney U test. We 
hypothesized that the longer the allopurinol treatment was given, the more effect this 
drug could have on vessel wall inflammation and on serum CXCL8 level. Therefore, to 
assess the effect of allopurinol on CXCL8 levels, the median CXCL8 level of the last 
sample was compared to the median CXCL8 level at baseline with the related-samples 
Wilcoxon signed rank test. In a subgroup analysis of 10 patients with the longest follow-
up and at least 4 assessments, serum UA and CXCL8 levels are shown over time. To 
investigate whether prescribed allopurinol resulted in an adequately lowered serum UA 
level in which urate depositions should be cleared from joints and subcutaneous tissues, 
the median UA level of the last sample was compared to the median UA level at baseline 
with the related samples Wilcoxon signed rank test.
Statistical significance was defined as P value <0.05. All statistical tests have been 
performed using IBM SPSS Statistics 21. For this study, no funding was used.
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Results
60 patients were included. Their mean (SD) age was 62 (14), and 50 (83%) of them were 
male. At baseline 50 (83%) patients had gouty joint inflammation, median (IQR) levels 
of UA, CRP, GFR and CXCL8 levels were 0.53 (0.45-0.57) mmol/l, 8 (3-28) mg/l, 72 
(55-86) ml/min, and 13 (6-19) pg/ml (figure 1), respectively. 4 (7%) patients had high 
levels of CXCL8 (>100 pg/ml), 31 (52%) intermediate levels (10-100 pg/ml), and 25 
(42%) low levels (<10 pg/ml). 46 (77%) patients had hypertension, 10 (17%) diabetes, 
and 27 (45%) one or more cardiovascular disease. There was a low correlation between 
CXCL8 and UA levels (R=0.32) and between CXCL8 and GFR levels (R=0.36), and 
no correlation between CXCL8 levels and CRP levels (R=0.04). Gout patients with 
one or more cardiovascular disease had significantly higher UA (P=0.001) and CXCL8 
(P=0.009) (figure 1) levels at baseline compared to patients without CVD, but no 
significant between group difference was seen for tophi and CRP level (table 1). 
	
Figure 1. Baseline individual CXCL8 levels, median and interquartile ranges of all patients, patients with cardiovascular 
diseases (CVD), and patients without CVD.
102
Chapter 6
Table 1. Baseline characteristics in gout patients with and without cardiovascular disease¹.
Clinical variable ≥1 cardiovascular disease 
(n=27)
No cardiovascular disease 
(n=33)
P value
Male sex, No. of patients (%) 18 (67) 32 (97) 0.003
Age, mean (SD) 69 (10) 56 (14) 0.000
Gouty joint inflammation, No. of patients (%) 22 (82) 28 (85) 0.7
Tophi, No. of patients (%) 10 (37) 10 (30) 0.6
Uric acid level (mmol/l), median (IQR) 0.56 (0.53-0.64) 0.46 (0.44-0.55) 0.2
CRP level (mg/l), median (IQR) 10.5 (3.0-34.8) 6.0 (2.0-25.0) 0.2
CXCL8 level (pg/ml), median (IQR) 17.3 (9.9-25.5) 9.3 (4.2-16.6) 0.009
¹Defined as angina pectoris, myocardial infarction, heart failure, cerebrovascular accident, transient ischemic attack, or 
peripheral vascular disease.
During follow-up, 9 patients had intermittent high (at least one value >100 pg/ml), 10 
patients had permanent low (all values <10 pg/ml) and 41 patients had intermediate 
(all values between 10 and 100 pg/ml) CXCL8 levels. After follow-up, the median 
(IQR) levels of UA and CXCL8 were 0.35 (0.29-0.40) mmol/l and 11 (5-19) pg/ml, 
respectively. The median UA level after follow-up was significantly lower (P<0.001) 
than the UA level at baseline after a median (IQR) follow-up of 27 (12-44) weeks. 33 
of 60 (55%) patients reached a UA level <0.36 mmol/l after follow-up. There was no 
significant difference between median CXCL8 after follow-up and at baseline (P=0.66). 
In all patients with the longest follow-up period and at least 4 assessments (n=10), UA 
and CXCL8 levels decreased (with in 9 of them UA <0.36 mmol/l; figure 2). After a 
year of follow-up (median (IQR): 51 (45-60) weeks) in 9 out of 10 patients CXCL8 
levels seemed to decrease slightly, in 3 patients after an initial increase. 
Discussion
The main conclusions of this study are that high CXCL8 levels are associated with 
CVD in gout patients. Relatively short-term use of allopurinol (median (IQR): 27 
(12-44) weeks) does not change CXCL8 levels in crystal proven gout patients, whereas 
there is a slight decrease of CXCL8 levels in a subgroup of patients using allopurinol 
approximately one year (median (IQR): 51 (45-60) weeks). Systemic inflammation 
is well-known as an accelerator for atherosclerosis. Although less well studied than in 
other chronic inflammatory rheumatic diseases (9) like rheumatoid arthritis, also in 
gout patients, there is evidence for increased atherosclerosis compared to the general 
population. Carotid ultrasonography showed more frequent subclinical atherosclerosis 
in gout patients compared to asymptomatic hyperuricemic patients (10). The 
mechanisms for systemic inflammation in gout patients are not fully clear, but CXCL8 
seems to be of interest in this. CXCL8 has a part in joint inflammation as CXCL8 
levels were increased in synovial fluid of gout patients (3). But also high levels of serum 
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CXCL8 were found in gout patients irrespective of disease activity (4), suggesting a 
role in systemic inflammation. High CXCL8 levels were observed in atherosclerotic 
plaques compared to normal vessel walls (11-15), and several studies showed relevancy 
for CXCL8 in predicting CVD (4, 10, 16, 17). To further study the role of CXCL8 in 
systemic inflammation in gout patients we hypothesized that (part of ) the well-known 
cardiovascular protective effect of allopurinol could be based on a direct or indirect 
reduction of CXCL8 levels and therewith reduction of vessel wall inflammation.
 
	
Figure 2. Serum CXCL8 and serum uric acid levels in the subgroup of 10 patients with the longest follow-up and at 
least 4 assessments.
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There are three potential mechanisms by which allopurinol could reduce vessel wall 
inflammation and therewith decrease of CXCL8 levels. First, allopurinol could decrease 
vessel wall inflammation via a direct pharmacological effect, and secondary also decrease 
serum CXCL8 levels. In the literature, there is evidence for this hypothesis. The 
enzyme xanthine oxidase converts hypoxanthine into UA and oxidative free radicals. 
Oxidative free radicals cause oxidative stress in the vessel wall, which leads to endothelial 
dysfunction and in the end CVD (18). Inhibition of xanthine oxidase by allopurinol 
could therefore have cardiovascular protective effects (19). A systematic review showed 
that xanthine oxidation inhibition by allopurinol improved endothelial function and 
decreased circulating markers of oxidative stress in patients with (increased risk of ) 
cardiovascular disease (20). Probenecid (6) and benzbromarone (5), both uricosurica, 
did not have favorable effects on endothelial function. These studies suggest that 
upregulated xanthine oxidase activity, rather than UA itself, is involved in endothelial 
dysfunction, and that allopurinol has a direct effect on vessel wall inflammation by 
downregulation of xanthine oxidase. In our study, gout patients who used allopurinol 
short-term did not show a decrease in CXCL8 levels, but patients who used allopurinol 
long-term did have a slight decrease in CXCL8 levels. Probably, time is needed after 
the direct effect of allopurinol on vessel walls before (decreased) CXCL8 serum levels 
could be associated to the reduced inflammation as a delayed secondary effect. Second, 
allopurinol-induced decrease of serum CXCL8 levels (and other cytokines) inhibits via 
a direct pharmacological effect vessel wall inflammation. Our data do not support this 
hypothesis since we did not find a fast/immediate decrease in serum CXCL8 levels. Third, 
allopurinol could decrease vessel wall inflammation via an indirect effect, via suppression 
of chronic subclinical joint inflammation, and secondary a decrease of serum CXCL8 
and other cytokine levels activity. As described above, in gout chronic subclinical joint 
inflammation is present. Gout is a deposition disease and time is needed before all urate 
crystals are fully removed from joints and subcutaneous tissues. After a longer period 
of allopurinol treatment in which the target UA level has been reached for one or two 
years, it is plausible that depositions of urate crystals are cleared, and as a consequence 
chronic subclinical joint inflammation decreases. Then CXCL8 is no longer needed in 
the inflammatory response and its production will diminish, which results in decreasing 
serum CXCL8 levels. This might be an explanation that we did not find a decrease in 
CXCL8 levels in our study, because of our short follow-up for most of our patients. 
Indeed, our subgroup analysis of 10 patients with longer follow-up showed a trend in a 
decrease of CXCL8 levels, sometimes after a previous increase. However, the patients in 
this subgroup had (almost all) reached their target UA, as a marker for disappearance of 
urate depositions, for only some weeks or months instead of one or two years. 
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A strength of our study is that all gout patients had urate crystal-proven gout. Our study 
has also several limitations. It was a pilot study with a pragmatic design, embedded 
in daily practice, to reveal whether a larger, methodologically improved study would 
be indicated. The pragmatic pilot design accounts for the small number of included 
patients, the at non-predefined moments taken serum samples, the different dosages of 
allopurinol, and the short duration of follow-up for some patients. A future randomized 
controlled clinical trial in which CXCL8 levels are measured in crystal proven gout 
patients during their therapy (allopurinol vs. placebo or uricosuricum) at regular time 
intervals, during at least one year of follow-up after reaching target UA levels could 
further elaborate on our findings.
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Abstract
Aim and background
Chronic inflammation associates with increased senescence, which is a strong predictor 
for cardiovascular disease. We hypothesized that inflammation accelerates senescence 
and thereby enhances the risk of cardiovascular disease in gout.
Methods
We assessed replicative senescence by quantifying telomere length (TL) in a discovery 
cohort of 145 Dutch patients with gout and 273 healthy individuals and validated 
our results in 474 patients with gout and 293 healthy participants from New-Zealand. 
Subsequently, we investigated the effect of cardiovascular disease on TL of all participants. 
Also, we measured TL of CD4+ and CD8+ T lymphocytes, B lymphocytes, monocytes, 
natural killer (NK) cells and plasmacytoid dendritic cells. Additionally, we assessed the 
potential temporal difference in TL and telomerase activity.
Results
TL in peripheral blood mononuclear cells of healthy donors decreased over time, 
reflecting normal ageing. Patients with gout demonstrated shorter telomeres (P=0.001, 
R2=0.01873). In fact, the extent of telomere erosion in patients with gout was higher 
at any age as compared to healthy counterparts at any age (P<0.0001, R2=0.02847). 
Patients with gout with cardiovascular disease had the shortest telomeres and TL was an 
independent risk factor for cardiovascular disease in patients with gout (P=0.001). TL 
was inversely associated with the number of gouty flares (P=0.005).
Conclusions
Patients with gout have shorter telomeres than healthy participants, reflecting increased 
cellular senescence. Telomere shortening was associated with the number of flares and 
with cardiovascular disease in people with gout.
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Introduction
Gout is a rheumatic disease characterized by deposition of monosodium urate (MSU) 
crystals in and around the joints, associated with elevated serum urate levels. Gout is the 
most common inflammatory arthritis in men older than 40 years and it affects 1-5% of 
adults in the Western populations (1–5) Patients experience recurrent episodes of acute 
joint inflammation and, in the presence of persistent hyperuricemia, may also develop 
chronic joint inflammation. We recently demonstrated that patients with gout display 
high levels of inflammatory mediators such as interleukin (IL) 8 even though these 
patients did not have clinically apparent inflammatory disease at the time of sample 
collection (6).
Chronic and recurrent inflammation activates the immune system, elevating the demand 
for immune cells, damaging tissues and forcing cell replication. This can ultimately 
eventuate a state of replicative senescence in most cells. Replicative senescence is 
when cells can no longer divide to form new cells. These senescent cells secrete pro-
inflammatory markers such as IL6 and IL1a (7). The most commonly used marker 
for replicative senescence is telomere length (TL). Telomeres function as a non-coding 
protective end-region of chromosomes. Due to the DNA end-replication inefficiency 
of polymerases, chromosomes shorten every cell division. After a certain number of 
divisions, the threshold of attrition is reached, cell-cycle arrest occurs and eventuates 
the senescent state. Telomeres therefore are indicative of the number of divisions the cell 
lineage has undergone and are a measure of replicative senescence.
Since recurrent and chronic inflammation leads to replicative senescence, which in turn 
contributes to a pro-inflammatory environment, measuring replicative senescence by 
TL has been a subject of scrutiny in inflammatory diseases (8). Telomere shortening has 
been repeatedly associated with multiple inflammatory diseases. Previously, TL has been 
associated with lifespan, although this remains controversial, and with cardiovascular 
disease (9). The latter association has been recently substantiated in a large meta-
analysis including over 50,000 individuals (10). This study showed a significantly 
increased relative risk for developing cardiovascular and cerebrovascular disease in the 
tertile of the population with the shortest telomeres. Causality between senescence and 
cardiovascular diseases is supported by the presence of a high number of senescent cells 
in atherosclerotic plaques, enhancing inflammation and decreasing recovery potential. 
Endothelial cells, vascular smooth muscle cells (VSMC) and immune cells are involved. 
The reduced proliferative capacity of endothelial cells and VSMCs, together with the 
pro-inflammatory environment lead to plaque instability, preluding vascular events 
(11–13).
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Gout is often accompanied by cardiovascular comorbid conditions including myocardial 
infarction and cerebrovascular events, which lead to an increased morbidity and decreased 
life span (14, 15). Gout is also associated with metabolic syndrome, diabetes and renal 
failure, which in turn are predictors for cardiovascular disease. However, patients with 
gout remain at higher risk for developing cardiovascular disease after correction for these 
variables (16).
We hypothesize that chronic and recurrent acute inflammation in gout accelerates 
replicative senescence, increasing the risk of cardiovascular disease. That is, patients with 
gout with the highest burden of replicative senescence, will also have the highest burden 
of cardiovascular disease. To test our hypothesis, we investigated the most studied 
hallmark of replicative senescence, TL of peripheral blood mononuclear cells (PBMCs) 
in two independent cohorts consisting of patients with gout and healthy individuals, 
both with and without cardiovascular disease. Also, we investigated telomere dynamics 
in various immune cell subsets, scrutinized TL in a follow-up cohort and quantified 
humane telomerase reverse transcriptase (hTERT) (encoding human telomere reverse 
transcriptase) gene expression.
Methods
Discovery cohort and validation cohort
In our discovery cohort, we compared TL of PBMCs in 145 patients with gout with 273 
Dutch participants (supplementary table 1). In our validation cohort, we assessed TL in 
PBMCs collected from 474 Caucasian patients with gout and 293 healthy participants 
participating from New Zealand (supplementary table 2).
This study was performed according to the guidelines of the Declaration of Helsinki 
and meets the ethical approval of the Ethical and Review committee of the University 
Medical Centre of Utrecht, Rijnstate Hospital in Arnhem (both Netherlands) and the 
Multi-Region Ethics Committee in New Zealand. All the participants in this study gave 
their informed consent to participate.
Isolation of mononuclear immune cell subsets
Mononuclear cell subsets were sorted from total PBMCs isolated by Ficoll (Ficoll-
Paque Plus, GE Healthcare) from peripheral blood of 10 Dutch patients with gout 
and 11 healthy participants (supplementary table 3). Sorting the mononuclear cell 
subsets was performed using fluorescence activated cell sorting (FACS) (FACSAria_III, 
BD Biosciences) to separate the cells according to the expression of cellular surface 
molecules; CD3+/CD56-/CD4+ for T helper lymphocytes, CD3+/CD56-/CD8+ for 
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cytotoxic T lymphocytes, CD19+/CD20+ for B lymphocytes, CD14
+
 monocytes, CD3
-/
CD56+ NK cells and CD123 (IL3RA)+ / CD304 (BDCA4)+ plasmacytoid dendritic cells 
(pDC)s.
Telomere length measurements
DNA of PBMCs was extracted using a standard salting-out protocol. Absolute TL 
quantification (17) modified with synthetic standards as described by O’Connell et al. 
was performed using the quantitative PCR method (18).
hTERT gene expression
hTERT gene expression level was quantified using synthesized cDNA (Biorad iScript kit) 
from RNA that was extracted from the PBMCs. Patients with gout (n=64) and healthy 
participants (n=89) from the Dutch cohort were randomly chosen. Quantstudio QPCR 
apparatus with TaqMan assay (Applied Biosystems) were used to perform QPCR under 
conditions as specified by the manufacturer. To normalize the hTERT gene expression, 
the housekeeping GUSB and GAPDH genes were included. A similar method was used 
to assess hTERT gene expression in 10 patients with gout and 11 healthy participants 
immune cell subtypes separately.
Statistical analyses
For statistical analysis, IBM SPSS Statistics v23 (SPSS, Chicago, Illinois 60606 USA) 
and GraphPad Prism v6 (GraphPad Software, San Diego, California, USA) applications 
were applied. TL (in kilobase pairs) of patients with gout and healthy participants 
were log-transformed to normalize the distribution. A two-tailed t-test was used when 
appropriate with Welch’s correction for comparing the unequal variances between the 
groups. Three independent linear regression models were applied to separately estimate 
(a) the interpolation between TL and age, gender, smoking, cardiovascular disease, heart 
failure, stroke (non-fatal), myocardial infarction (non-fatal), angina pectoris, systolic 
and diastolic blood pressure, body mass index (BMI) (kg/m2), serum uric acid (UA) 
level (mmol/l) and creatinine level (µmol/l) in patients and healthy individuals; (b) 
the association between TL and the presence of cardiovascular events (heart failure, 
stroke (non-fatal), myocardial infarction (non-fatal), angina pectoris and age) severally 
in individuals with gout; and (c) the relation between TL and gout hallmarks including 
attack frequency, age at the first attack, disease duration, serum UA level (mmol/l), 
creatinine level (µmol/l) severally in patients group (table 2).
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In addition, the difference in TL between gout patients with or without cardiovascular 
events (a) and separately the association between flare frequency and cardiovascular 
events (angina pectoris, heart failure, myocardial infarction (non-fatal) and stroke (non-
fatal)) (b) are represented in supplementary table 4. Univariate analysis was performed 
to examine the effect of variables such as gender, age, smoking, BMI and creatinine levels 
on TL (supplementary table 5). Where appropriate, two-tailed Pearson’s or Spearman’s 
bivariate correlations were applied to assess the correlation between the variables 
(P<0.05). The Bonferroni correction was applied to account for multiple testing.
Table 1. Baseline characteristics of Dutch and New Zealand patients and healthy participants.
  Gout 
(n=619)
Healthy participants 
(n=566)
P value
Male, n (%) 489 (79.00) 398 (70.32) 0.247
Age, mean ± SD 62.8 ± 14.15 59.60 ± 13.67 0.0001
Age at the first flare, mean ± SD 51.12 ± 16.75 - -
Disease duration (year), mean ± SD 12.90 ± 12.28 - -
Colchicine (yes), n (%) 254 (50.50) 1 (0.17) 0.247
NSAID (yes), n (%) 353 (75.50) 2 (0.35) 0.433
Allopurinol (yes), n (%) mean 200mg/day 337 (67.10) 1 (0.17) 0.0001
Corticosteroids (yes), n (%) 197 (40.20) 1 (0.17) 0.643
CVD (yes), n (%) 270 (43.62) 43 (7.59) 0.0001
Diabetes, type 2 (yes), n (%) 87 (14.02) 19 (3.36) 0.0001
Stroke (yes), n (%) 43 (6.95) 67 (11.83) 0.0001
Myocardial infarction, non-fatal (yes), n (%) 70 (8.60) 66 (11.60) 0.054
Heart failure (yes), n (%) 70 (11.31) 64 (11.31) 0.270
Angina pectoris (yes), n (%) 37 (5.98)  7 (1.24) 0.0001
Creatinine level (µmol/l), mean ± SD 105.73 (± 39.38) 93.44 (± 30.29) 0.0001
Body mass index (kg/m2), mean ± SD 29.73 (± 5.60) 28 (±6.37) 0.0001
Smoking (yes), n (%) 51 (8.24) 5 (0.90) 0.0001
Serum urate (mmol/l), mean ± SD 0.43 (± 0.13) 0.35 (± 0.10) 0.0001
Total number of flares per year, mean ± SD 8.75 ± (12.67) - -
Presence of tophi (yes), n (%) 116 (21.40) - -
Systolic blood pressure (mm Hg), mean ± SD 139.90 (± 20.55) 136 (± 17.64) 0.039
Diastolic blood pressure (mm Hg), mean ± SD 80.40 (± 11.83) 80.00 (± 9.62) 0.559
Telomere length (total leukocytes), mean +- SD 5924.90(±8617.76) 8242.70 (± 8482.00) 0.0001
The significance of the association between the 2 classified subgroups of gout and healthy participants was tested using 
Fisher’s exact test (categorical values) and Mann–Whitney U test (non-parametrical continues values) (P<0.05).
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Results
Demographics
Baseline characteristics of participants from the Netherlands and New Zealand are 
summarized in table 1.
PBMCs from patients with gout have shorter telomeres compared to their healthy 
counterparts in two unrelated cohorts
Within our Dutch discovery cohort, we analyzed the TL of PBMCs of 273 healthy 
participants and 145 patients with gout and correlated the results with their age in 
year. The TL in patients with gout was significantly shorter than healthy participants 
(supplementary table 1). In patients with gout, linear regression analyses 
demonstrated no association between age and TL (P>0.05, R2=0.002853) (telomere 
shortening=0.002082*age+4.01). This was in contrast to the significant inverse/negative 
correlation between TL and age in healthy participants (P<0.0001, R2=0.3721) (telomere 
shortening=-0.02180*age+5.31) (supplementary figure 1). 
Next our results in the independent cohort of NZ Caucasian, showed that TL was 
significantly shorter in patients with gout (n=474) as compared to healthy participants 
(n=293) (supplementary table 2). Moreover, we found a negative association 
between TL and age in gout patients (P=0.0014, R2=0.02276) (telomere erosion= 
-0.004926*age+3.51). In healthy participants, we found a negative association with age 
(P<0.0001, R2=0.111) (telomere erosion=-0.01089*age+3.94) (supplementary table 2 
and supplementary figure 2).
Given the similarities in TL of PBMCs in both the discovery and replication cohort, we 
pooled the data (figure 1). When corrected for age, patients with gout have significantly 
shorter telomeres in PBMCs as compared to healthy participants (P<0.0001). TL 
correlates negatively with age in patients with gout (P=0.0010, R2=0.01873) (TL=-
0.006084*X+3.79). Similarly, PBMCs TL in healthy participants was inversely 
correlated with age (P<0.0001, R2=0.02847) (TL=-0.006349*X+3.99).
Finally, we had access to follow-up data on TL from 9 patients with gout involved in the 
Dutch cohort of whom 88.9% were male 46-87 years old with a median age of 63 years. 
The time period between the inclusion date and the follow-up at the second time point 
was from 1 to 11 month with an average of 4.33 months. There was no (P=0.34) change 
in TL of the same patients with gout measured at two different time points (T1=4.20 
kbp and T2=4.29 kbp).
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Figure 1. Log-transformed telomere length (kbp) of PBMCs of patients with gout and healthy participants consistent 
with age (years). Patients with gout (filled dots) (N=619) have shorter telomeres at young age and the telomere length 
remains short in older patients with gout (p=0.001). Young healthy participants (empty dots) (N=566) represent longer 
telomere compared with older individuals ( p<0.0001). Overall telomere length of patients with gout is significantly 
shorter compared with healthy participants (p<0.0001). Statistical analysis between the two groups was performed using 
two-tailed Student’s t-test (Mann–Whitney correction). Correlation between telomere length and age was tested through 
linear regression model.
Gout and cardiovascular disease have an independent and cumulative effect on 
telomere attrition
Since gout is strongly associated with cardiovascular disease, and cardiovascular disease 
has been associated with shorter telomeres, we investigated their separate effects. We 
included both patients with gout and participants with chronic heart disease, non-
fatal myocardial infarction, non-fatal stroke and angina pectoris (figure 2). Consistent 
with previous reports, healthy participants without cardiovascular disease had longer 
telomeres (P=0.04) as compared to healthy participants with cardiovascular disorders. 
The presence of cardiovascular disease in patients with gout resulted in significantly 
shorter telomeres (P=0.0001) compared to individuals with gout only. Moreover, TL in 
patients with gout without cardiovascular disease was shorter (P=0.0037) as compared 
to matched healthy individuals (figure 2). Consequently, both gout and cardiovascular 
disease eventuated even shorter telomeres compared to healthy participants (P=0.005). 
Patients with cardiovascular disease concomitant with gout, demonstrated shorter 
telomeres (P<0.0001) as compared to healthy individuals without any comorbidities.
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Figure 2. Log-transformed leucocytes’ telomere length (kbp) of pooled Dutch and New Zealand patients with gout 
and healthy participants stratifi ed according to (A) cardiovascular disease (CVD) (yes/no) and (B) the level of creatinine 
(mmol/L). (A) Leucocytes’ telomere length of patients with gout (N=325) and healthy participants (N=183) without 
(–) or with (+) (N gout=294) (N healthy participant=383) CVD (chronic heart disease, non-fatal stroke, non-fatal 
yocardial infarction and angina pectoris) is represented. (B) Leucocytes’ telomere length of patients with gout and 
healthy participants stratifi ed according to the plasma level of creatinine (mmol/L). Th e threshold of plasma creatinine 
was set at 100 mmol/L and below the threshold, creatinine levels of patients with gout and healthy participants are 
represented as normal (fi lled/empty bullets) and subsequently above the threshold are represented as high. (N gout 
normal creatinine=219) (N gout high creatinine =214) (N HC normal creatinine =208) (N HC high creatinine =92). 
Box plot is represented with minimum and maximum range. Statistical diff erences were tested using Mann-Whitney U 
test (*p<0.05 was considered as signifi cant).
In the linear regression model involving both patients with gout and healthy individuals, 
gout (P=0.008), cardiovascular disease (P=0.023) and heart failure (P=0.01) were 
independently infl uencing TL (table 2A). Of note, although all the continuous variables 
mentioned in table 2 were included in this model, gout, cardiovascular disease and heart 
failure remained in the model as signifi cantly associated with TL. Moreover, in a linear 
regression model, cardiovascular disease (P=0.001) and myocardial infarction (P=0.016) 
infl uenced telomere attrition in the gout population (table 2B). Additionally, in a 
separately performed independent linear regression model, the age at the fi rst gout event 
(P=0.04), frequency of gouty fl ares (P=0.005) and the disease duration (P=0.035) were the 
most signifi cant hallmarks of gout associating with shorter telomeres (table 2C).
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Table 2. Multiple linear regression models for telomere length (TL) measurements in patients and healthy participants.
    Number of participants Standardized β Standard error P value
A Gout 619 -0.23 0.01 0.008
Cardiovascular disease 313 -0.19 0.02 0.023
  Heart failure 134 -0.22 0.01 0.010
B Cardiovascular disease 270 -0.55 0.02 0.001
  Myocardial infarction (non-fatal) 70 -0.40 0.01 0.016
Mean ± SD Standardized β Standard error P value
C Multiple number of flares 8.75 ± 12.67 -0.30 2.02 0.005
Age at the first attack 51.12 ± 16.75 -0.05 0.71 0.040
  Disease duration 12.90 ± 12.28 -0.22 0.52 0.035
Table 2A. Demonstrates the variables significantly associated with TL involving patients with gout and healthy individuals 
assessed using multiple linear regression model. Age, gender, smoking, cardiovascular disease, heart failure, stroke (non-
fatal), myocardial infarction (non-fatal), angina pectoris, systolic and diastolic blood pressure, BMI (kg/m2), serum uric 
acid level (mmol/l) and creatinine level (µmol/l) were included in the model as independent variables (P<0.05).
Table 2B. Includes the results of multiple linear regression analysis associating TL with cardiovascular events (heart 
failure, stroke (non-fatal), myocardial infarction (non-fatal), angina pectoris and age only in individuals with gout 
(P<0.05).
Table 2C. Represents multiple linear regression analysis results where the association between TL and gout hallmarks 
(attack frequency, age at the first attack, disease duration, serum uric acid level (mmol/l), creatinine level (µmol/l)) was 
tested (P<0.05).
Furthermore, analysis revealed significantly shorter telomeres in patients with gout 
and cardiovascular events compared to gout patients without cardiovascular events 
(supplementary table 4A). According to the linear regression model, however, there 
was no association between the flare frequency and cardiovascular events in patients 
with gout (supplementary table 4B).
Treatment might inhibit inflammation-induced telomere erosion in immune cells 
of patients with gout
Since the majority of patients with gout were receiving anti-inflammatory and/or urate-
lowering treatment, we tested if any treatment had any effect on the extent of telomeres. 
The treatment included allopurinol (mean 200 mg/day), colchicine, corticosteroids, 
NSAIDs or a combination of these drugs. There was no significant difference between 
TL of treated (TL ± SD 2301 ± 2333.79) and untreated patients (TL ± SD2998 ± 
5166.92) (n=23) (P=0.584). The insignificant difference in TL might be due to low 
number of untreated patients. Since the patients were treated with more than one drug, 
any drug specific effect on the extend of TL was intractable.
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Telomere shortening is not specifi c for certain immune cell subsets
To identify immune cells with a dominant eff ect on the complications associated with 
senescence, we investigated the percentage and TL of mononuclear cellsubsets of 10 
healthy participants and 10 patients with gout (supplementary table 3).
In patients with gout, there were no signifi cant diff erence in CD4+ T lymphocytes 
(24.42%), CD8+ Cytotoxic T lymphocytes (6.74%), CD19+ B lymphocytes (7.02%), 
CD14+ monocytes (7.75%), NK cells (7.92%) and CD123+/CD304+ pDCs (0.02%) of 
patients with gout as compared to healthy participants’ cell-subsets that were 33.19% 
(P=0.11), 8.98% (P=0.061), 10.07% (P=0.157), 6.28% (P=0.90), 7.38% (P=0.52) and 
0.11% (P=0.8) respectively (Mann-Whitney U-test, P<0.05).
Moreover, CD19+ B lymphocytes of patients with gout had the longest telomeres and 
CD123+/CD304+ pDCs the shortest. Th e longest and shortest telomeres in healthy 
participants were also respectively in CD19+ B lymphocytes and CD123+/CD304+ 
pDCs. In direct comparison between cell-subsets from patients with gout and healthy 
individuals we did not observe a signifi cant diff erence in TL.
Telomerase activity is similar in patients with gout and healthy participants
Th ere was no correlation between hTERT gene expression level and TL in total PBMCs. 
Th ere was no signifi cant diff erence in the mean fold change of hTERT expression level 
of patients with gout (P=0.921, R2=0.013) and healthy participants (P=0.087, R2=-
0.264) (fi gure 3). Similarly, there was no correlation between hTERT gene expression 
level and TL of the immune cell subset (supplementary table 3).
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Figure 3. Log human telomerase reverse transcriptase (hTERT) gene expression level (FC) of Dutch patients with gout, 
measured using PBMCs’ RNA and quantitative PCR method. hTERT gene expression levels between patients with gout 
(N=64) and healthy participants (N=89) are not signifi cant (statistical diff erences were tested using Mann-Whitney U 
test) (*p<0.05 was considered as signifi cant). Error bars represent box plot with minimum and maximum range.
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Discussion
In this study, we show that patients with gout have shorter telomeres than healthy 
participants, reflecting increased cellular senescence. Telomere shortening was strongly 
associated with the number of gouty flares. Both gout and cardiovascular disease were 
independently associated with shorter telomeres. This is to our knowledge the first study 
to show telomere erosion in patients with gout compared to healthy participants.
There are several strengths of this study that minimize the risk of chance observation or 
population bias. We exploited an independent replication cohort where DNA material 
was isolated and measured using a similar protocol. We observed intriguing TL differences 
in participants of both Dutch and New Zealand cohorts. It has been described previously 
that there are large differences in telomere length between Caucasians from different 
European descent. For instance, telomeres of inhabitants from Belgium have been 
shown to be six-fold longer as compared to inhabitants from Italy and are approximately 
twice as long as inhabitants from the United Kingdom, Ireland and Scotland (19,20). 
Since the Caucasians from New Zealand have ancestors primarily from Britain and the 
Dutch are more closely related to the Belgians, our findings are most likely caused by an 
ancestral difference (20–22).
To rule out an effect of differences in telomere maintenance between patients with gout 
and healthy participants, we tested hTERT gene expression which has been shown to 
be a reliant proxy marker to measure telomerase activity (22). We assessed hTERT gene 
expression in PBMCs and cell subsets of patients with gout and healthy individuals. We 
did not observe any difference in hTERT gene expression level which underscores any 
bias due to telomerase activity as very unlikely. To minimize technical issues, we used the 
same protocols and same machines to measure TL.
To elucidate more details on underlying facets contributing to telomere attrition in gout, 
we quantified absolute TL in CD4+ and CD8+ T cells, CD19+ B cells, CD14
+
 monocytes, 
NK cells and pDCs in patients with gout and matched healthy participants. TL of CD4+ 
and CD8+ T cells, CD19+ B cells, CD14
+
 monocytes, NK cells and pDCs showed no 
significant difference. In immune cell subtypes of patients with gout, telomere shortening 
showed a slightly declining trend as compared to healthy participants. However, the 
number of included participants is insufficient to empower us to draw definite conclusions 
from these results. Multiple research groups have corroborated a strong link between 
chronic inflammation and decrease of TL in cell-subsets. For instance, studies on HIV 
elucidated the link between chronic infection and telomere attrition in CD4+  and CD8
+ 
T cells (23, 24). The replicative senescence of T lymphocytes is not limited to HIV, since 
it is broadly investigated in association with malignancies (25), autoimmune disorders 
(26) and environmental mediators (27, 28). In autoimmune diseases, telomere erosion 
in lymphocytes has been less well delineated. Telomere erosion in CD14+ monocytes, 
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however, was shown to be significantly associated with pro-inflammatory behavior and, 
of high relevance for our findings, thereby accelerated atherosclerotic plaque formation 
(29). In the elderly, diminished NK cell function was significantly associated with the 
extent of telomere erosion (30, 31). The literature describing telomere attrition in pDCs 
is rather poor and requires additional investigations. Taken together, it is known from 
the literature that TL of various immune cell subsets can be impacted when chronic 
or recurrent inflammation is present. In our study, we could not pinpoint a single cell 
subset responsible for the shortening of telomeres as observed in the PBMCs from the 
gout population. Since the effects on TL difference in PBMCs only came apparent in 
a large cohort with hundreds of patients, we believe that our lack of findings is most 
likely caused by a lack of power in the subset analyzes. On the other hand, since we 
observe such similar findings between subsets, it seems to indicate that there is not one 
single cell subset responsible for a large effect on TL in the whole PBMC population. 
The latter might point to a more generalizable effect in the cell-subset populations. 
Additionally, the shifting of naïve T lymphocytes towards a memory-like subset remains 
to be delineated. whereby the CD28 marker repertoire might be indicative of chronic 
inflammation-induced activation in T lymphocytes (32).
We conclude that the shorter telomeres observed in the gout population are most 
likely caused by increased PBMCs turnover due to ongoing or frequent inflammatory 
episodes. This is consistent with association of reduced TL with increased flare frequency. 
In various tissues and cell subtypes, accelerated cell turnover is inversely associated 
with replicative senescence. In disorders involving accelerated oxidative injury and 
chronic immune system activation as the main manifestation, such as systemic lupus 
erythematosus (33), rheumatoid arthritis (32) and systemic sclerosis (34), enhanced 
cell-turnover and telomere erosion has been extensively described. Furthermore, we 
observed no significant TL difference in treated patients with gout as compared to 
patients without treatment. In addition, patients with the most frequent flares had the 
shortest telomeres. This might indirectly imply a modulating effect of inflammation on 
telomere length and thereby replicative senescence.
The results of our study underline the strong association between inflammation, 
senescence and cardiovascular disease, as suggested previously (35). Recently, it 
has become apparent that rheumatic diseases confer risk of cardiovascular disease 
development. In rheumatoid arthritis, this risk approaches the risk of patients with 
diabetes (36). The pathogenesis of this increased risk is largely enigmatic, but is proposed 
to arise from a chronic inflammatory environment, causing vascular damage and plaque 
formation (37, 38). The occurrence of atherosclerotic plaques has been related to an 
increasing chronological age (11). On the other hand, there is a large role for biological 
ageing as well which has been demonstrated by the influx of pro-inflammatory senescent 
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immune cells in the plaque contributing to plaque instability and rupture and eventually 
cardiovascular and cerebrovascular events (39). The connection between replicative 
senescence and the presence of cardiovascular disease has been described before in the 
literature (40). Likewise, the prevalence of myocardial infarction in the elderly with 
shorter leukocytes’ TL is about three times higher (41, 42, 40). A recent systemic review 
confirmed this association by combining the telomere data and vascular morbidity of 
>50,000 individuals (10).
In summary, we present decreased TL as a feature of gout and confirm TL as an 
independent factor associated with flare frequency and cardiovascular disease. These 
data suggest that intensive treatment of gout may prevent replicative senescence and 
subsequently reduce the associated cardiovascular risk. However, large prospective 
studies are needed to test this possibility.
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Supplementary figure 1. Log transformed telomere length (kbp) of PBMCs of patients with gout and healthy individuals 
participating in Dutch cohort consistent with age (years). Patients with gout (N=145) have shorter telomeres at young 
age and the TL remains short in older patients with gout (P>0.05). Young healthy participants (N=273) represent 
longer telomere as compared to older individuals (P<0.0001). Overall TL of patients with gout is significantly shorter as 
compared to healthy participants (P<0.0001). Statistical analysis between the two groups was performed using two tailed 
Student T-test (Mann-Whitney correction). Correlation between TL and age was tested through linear regression model.
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Supplementary figure 2. Log transformed telomere length (kbp) of PBMCs of patients with gout and healthy individuals 
participating in New Zealand cohort consistent with age (years). Patients with gout (N=474) have shorter telomeres at 
young age and the TL remains short in older patients with gout (P=0.001). Young healthy participants (N=293) represent 
longer telomere as compared to older individuals (P<0.0001). Overall TL of patients with gout is significantly shorter as 
compared to healthy participants (P<0.0001). Statistical analysis between the two groups was performed using two tailed 
Student T-test (Mann-Whitney correction). Correlation between TL and age was tested through linear regression model.
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Supplementary table 1. Baseline characteristics of patients with gout and healthy participants in the Dutch cohort.
  Gout (n=145) Healthy participants (n=273) P value
Male, n (%) 91 (62.76) 190 (69.70) 0.0001
Age, mean ± SD 63 ± 9.85 62 ± 14.11 0.0001
Telomere length, mean ± SD 
(total PBMC)
11215.33 ± 8042.54 18014.77 ± 9548.66 0.0001
The significance of the association between the 2 classified subgroups of patients with gout and healthy individuals 
was tested using Fisher’s exact test (categorical values) and Mann–Whitney U test (non-parametrical continues values) 
(P<0.05).
Supplementary table 2. Baseline characteristics of patients with gout and healthy participants in the New Zealand 
cohort.
  Gout (n=474) Healthy participants (n=293) P value
Male, n (%) 388 (81.86) 233 (85.35) 0.0001
Age, mean ± SD 64 ± 12.82 55 ± 16.59 0.0001
Telomere length, mean ± SD
(total PBMC)
2524.55 ± 3478.42 5151.93 ± 7674.79 0.0001
The significance of the association between the 2 classified subgroups of patients with gout and healthy individuals 
was tested using Fisher’s exact test (categorical values) and Mann–Whitney U test (non-parametrical continues values) 
(P<0.05).
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Supplementary table 3. Baseline characteristics of patients with gout and healthy participants in immune cell-subsets.
Gout  
(n=10)
Healthy participants  
(n=11)
P value
Male, n (%) 8 (80) 10 (91) >0.05
Age 59 ± 16.27 45 ± 12.88 >0.05
Age at the first flare 53 ± 5.76 - -
Disease duration (year) 5.70 ± 2.77 - -
Colchicine (yes), n (%) 2 (20) N.A. -
NSAID (yes), n (%) 1 (10) N.A. -
Allopurinol (yes) 3 (30) N.A. -
(mean 200mg/day) 
Corticosteroids (yes), n (%) 2 (20) N.A. -
CVD (yes), n (%) 6 (60) N.D. -
Diabetes (type 2) (yes), n (%) 6 (60) N.D. -
Hypertension (yes), n (%) 4 (40) N.D. -
Creatinine level (µmol/l) 109.00 (± 25.09) N.D. -
BMI (kg/m2) 32.58 (± 8.51) N.D. -
Smoking (yes), n (%) N.D. N.D. -
Serum urate (mmol/l) N.D. N.D. -
Number of flares 19.70 ± 6.63 N.A. -
Presence of tophi (yes), n (%) 4 (40) N.A. -
Systolic blood pressure mean N.D. N.D. -
(mm Hg)
Diastolic blood pressure mean N.D. N.D. -
(mm Hg) 
Telomere length CD3+/CD4+ 15247.68± 13956.01 7339.70 ± 5063.97 >0.05
Telomere length CD3+/CD8+ 13036.82 ± 7838.27 6987.34 ± 5666.97 >0.05
Telomere length CD19+/CD20- 23374.06 ± 25676.88 8620.14 ± 6476.89 >0.05
Telomere length CD14+/CD16- 10988.64 ± 4523.27 6864.43 ± 5103.57 >0.05
Telomere length CD3-/CD56+ 12599.09 ± 27954.54 5310.30 ± 1747.49 >0.05
Telomere length CD123+/CD304+ 2804.35 ± 2536.15 4052.95 ± 4776.86 >0.05
hTERT CD3+/CD4+ 0.00112 ± 0.000240 0.00068 ± 0.000130 >0.05
hTERT CD3+/CD8+ 0.00028 ± 0.000040 0.00036 ± 0.000100 >0.05
hTERT CD19+/CD20- 0.00039 ± 0.000054 0.00139 ± 0.001120 >0.05
hTERT CD14+/CD16- 0.00018 ± 0.000041 0.00004 ± 0.000020 >0.05
hTERT CD3-/CD56+ 0.00030 ± 0.000001 0.00012 ± 0.000080 >0.05
hTERT CD123+/CD304+ N.D. N.D. -
The data are presented as mean ± SD. The significance of the association between the 2 classified subgroups 
of patients with gout and healthy participants was tested using Fisher’s exact test (categorical values) and 
Mann–Whitney U test (non-parametrical continues values) (P<0.05) (N.D.=not defined, N.A.=not 
applicable).
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Supplementary table 4. Telomere length differences between gout participants with or without cardiovascular disease 
(A) and the association of cardiovascular disease with the flare frequency in the gout population (B).
  A) Telomere length (bp) in gout population with 
or without cardiovascular disease
B) Multivariate linear regression on 
flare frequency and cardiovascular 
diseases in gout population
  Yes (SD) No (SD) P value Standardized β
Standard 
error
P value
Cardiovascular disease 2187 (1934.10) 6154 (8938.23) 0.0001 -1.35 1.82 0.459
Angina pectoris 2223 (2625.17) 5527 (7805.88) 0.0001 -2.94 3.07 0.340
Heart failure 4656 (28288.80) 13712 (28141.32) 0.015 -3.28 2.57 0. 203
Myocardial infarction 2165 (2397.07) 7272 (10916.47) 0.0001 -4.50 2.62 0. 063
Stroke 2182 (2378.78) 4784 (8980.58) 0.0001 -3.32 2.83 0.242
Telomere length (SD) in patients with gout with cardiovascular disease, angina pectoris, heart failure, myocardial 
infarction (non-fatal) and stroke (non-fatal) as concomitant disorders. A) The significance of the association between 
the 2 classified subgroups of gout participants was tested using Mann–Whitney U test. B) The association between the 
same variables (cardiovascular comorbidities) and the flare frequency was tested in a multiple variable linear regression 
model (P<0.05).
Supplementary table 5. The effect of additional co-variables on telomere length of patients with gout and healthy 
participants separately.
  Gout Healthy participant
Correlation 
Coefficient (R2)
P value Correlation 
Coefficient (R2)
P value
Gender -0.023   0.574 0.173 0.001
Age (years) -0.102   0.014 -0.315 0.0001
Smoking (yes/no) 0.418   0.0001 -0.041 0.669
BMI 0.031   0.459 0.080 0.175
Creatinine (mmol/l) -0.205   0.0002 -0.203 0.001
The statistical significance of the data is tested using two-tailed Spearman’s bivariate correlation (P<0.05).
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General discussion
There were two main objectives of this thesis: to obtain more insight in a reliable 
diagnosis of gout, and in the role of chronic systemic inflammation in gout and in the 
associations with comorbidities like cardiovascular diseases. Both objectives are clinically 
relevant with respect to the care of patients with this frequently occurring and disabling 
rheumatic disease. This care demands a reliable diagnosis in order to provide patients the 
right treatment and serious medical attention to suppress their signs and symptoms and 
reduce their elevated cardiovascular risks. In this general discussion overall conclusions 
of this thesis are drawn, the performed research is discussed, and recommendations for 
daily practice and for future research are given.
Diagnosis of gout
The gold standard in diagnosing gout is aspiration of synovial fluid (or tophaceous 
material) and identification of MSU crystals with polarization light microscopy. In many 
situations, such as in primary care and at the emergency departments, this gold standard 
is not accessible or applied because the physician feels confident about his or her clinical 
skills (1-4). However, an earlier study has already demonstrated a limited predictive value 
of the diagnosis of gout based on clinical signs and symptoms by primary care physicians 
(5). Chapter 2 of this thesis confirms again the limited value of the clinical skills in patients 
with monoarthritis of MTP1 (podagra), the hallmark of gout. Especially patients with a 
very typical presentation for a specific disease have a risk of misdiagnosis, because other 
diagnoses are easily overlooked. Further, polarization microscopes are expensive and almost 
only available at rheumatology departments. Training is necessary for correct analysis of 
joint fluid and microscopy can be very time consuming (6-8). But approximately 90% of 
the gout patients are diagnosed and treated by primary care physicians (9). Referral of all 
patients with presumable gout aiming for a gold standard diagnosis would increase the 
workload for rheumatologists enormously with considerable logistic and financial impact, 
especially when considering the increasing prevalence of gout (10-12). If synovial fluid 
analysis could be split in two separate procedures (1. joint aspiration and 2. analysis for 
identification of MSU crystals in synovial fluid with polarization light microscopy), then 
the first part could be done by a non-rheumatologist physician, e.g. in primary care or at 
emergency departments, and the diagnostic part by the rheumatologist or other trained 
expert. The primary care physician can send the aspirated synovial fluid to a rheumatology 
department. In contrast to the longstanding opinion that synovial fluid should be analyzed 
with a polarization light microscope fresh after aspiration, we have shown in chapter 3 of 
this thesis that long-term storage does not impede the reliability of the detection of MSU 
crystals. Just like a radiologist performs and analyzes an X-ray or ultrasound and reports his 
findings to the primary care or other physician, a rheumatologist or other trained expert 
could do the same with previously aspirated synovial fluid. 
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Selected use of synovial fluid analysis only in those patients with doubts about the 
diagnosis leads to better allocation of this (expensive) diagnostic test and better cost-
effectiveness. To achieve this selection of patients, the diagnosis of gout based on clinical 
signs and symptoms should be improved, considering the limited predictive value of 
this method of diagnosing by physicians (chapter 2) (5). Several criteria sets have been 
developed in earlier studies to improve the validity of the clinical diagnosis (13-16). In 
2010 an easy-to-use gout decision rule was developed in a primary care population and 
it showed good sensitivity and specificity (5). This diagnostic tool consists of 7 variables 
with weighted scores: male sex (2 points), previous arthritis attack (2 points), onset <1 
day (0.5 point), joint redness (1 point), involvement of the MTP1 joint (2.5 points), 
hypertension or one or more cardiovascular disease (1.5 point), and serum uric acid 
>5.88 mg/dl (equal to 0.35 mmol/l) (3.5 points). The advantage of this gout decision 
rule is that all clinical parameters can be easily obtained. In chapter 4 (and chapter 4a) 
we have validated this gout decision rule in a secondary care population and found a 
similar reliability as in the primary care population. In the meantime, the usefulness of 
this gout decision rule has also been shown in distinguishing between septic arthritis 
and gout (17), in Thai (18) and in mixed descent (19) secondary care patients. Patients 
with a monoarthritis can be divided in three groups by using the outcome scores of the 
gout decision rule. A low score (≤4 points) implicates that the arthritis is non-gout in 
almost all (95%) of the patients. A high score (≥8 points) means that the arthritis is gout 
in 87% of the patients. In patients with a score between 4 and 8 there is uncertainty 
about the diagnosis. In this group of patients with an uncertain diagnosis synovial fluid 
analysis should be performed. Therefore the patient could be referred to a rheumatologist 
or the non-rheumatologist physician can perform joint aspiration and send the synovial 
fluid to a rheumatologist for analysis. 
By using the above described algorithm for diagnosing gout, a reliable diagnosis becomes 
available for almost all patients regardless of the local circumstances and (financial) 
possibilities. And in case that synovial fluid analysis is not available at all, for example 
in less developed countries, the patient with a score between 4 and 8 on the diagnostic 
rule should be followed-up. In case of a recurrent arthritis the patient should be assessed 
again. If for instance this is the second arthritis attack the patients receives 2 points for 
‘previous arthritis attack’ and then the diagnosis of gout could become more probable. 
If for example recurrent arthritis attacks are never in the MTP1 joint and the serum uric 
acid remains <5.88 mg/dl then a non-gout diagnosis becomes more likely. 
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Chronic systemic inflammation and comorbidities in gout
When a reliable diagnosis of gout is made, the necessary therapeutic management can be 
started, including care for comorbidities. The last decades have shown increasingly that 
gout is associated with cardiovascular diseases, though the underlying pathophysiologic 
mechanisms are only partially known. Chronic systemic inflammation might play an 
important role. 
This thesis gives more insight whether chronic systemic inflammation is present in 
(chronic) gout patients. Earlier, in particular in vitro, studies have shown that the 
proinflammatory cytokines, and especially IL1β, are essential in the development of 
a gout attack (20-24). In chapter 5 of this thesis proinflammatory cytokines (CXCL8, 
IL1β, IL6, IL10, IL12 and TNF) were measured in serum of gout patients. Remarkably, 
not IL1β but CXCL8 levels were high in serum of gout patients during gout attacks 
but also in the intercritical phase of the disease, signaling ongoing inflammation with 
a possible consequence of, amongst others, vascular damage as CXCL8 is linked to 
atherosclerosis (25, 26). IL1β production is initiated by inflammasome activation, but 
CXCL8 production is not. An explanation for the high levels of CXCL8 might be that 
MSU crystals stimulate activation of macrophages, and that these macrophages activate 
the inflammasome but also produce high levels of CXCL8. Not only macrophages in 
joints but also in vascular walls can be triggered to produce CXCL8 (27, 28). Follow-up 
data of consecutive serum CXCL8 levels in gout patients presented in chapter 6 show 
that CXCL8 levels fluctuate over time and top values are not unconditionally connected 
with acute gout. This supports the hypothesis that in gout patients not only macrophages 
in joints produce CXCL8 but also in the vascular wall. In diseases characterized by 
chronic systemic inflammation such as rheumatoid arthritis there is an increased cellular 
senescence, measured by shorter telomere length (29). Also in gout patients shorter 
telomeres are present (chapter 7) suggesting that gout is a chronic inflammatory disease 
with an early senescence. Altogether, this thesis describes arguments to consider gout as 
a chronic inflammatory disease instead of an intermittent joint disease with implications 
for the follow-up and the treatment of the patient. Future studies should elucidate if 
chronic disease control, i.e. chronic uric acid lowering therapies, are better for the 
outcome of the patient than intermittent disease control by treating the acute attack 
only. 
In this thesis the association between chronic systemic inflammation and comorbidities, 
especially cardiovascular diseases, was investigated in patients with gout. Being a 
characterizing feature of chronic systemic inflammation in gout, serum CXCL8 levels 
were not associated with cardiovascular comorbidities, though high serum CXCL8 
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levels in gout patients did associate with diabetes mellitus (chapter 5). On theoretical 
grounds an association between CXCL8 and cardiovascular diseases is likely (27, 28), 
and we assume that we could not confirm this due to the low number of gout patients 
having cardiovascular diseases without diabetes mellitus in our study. This assumption 
is supported by the finding that we did report an association between the proteome 
profiles of high CXCL8 and cardiovascular diseases, and with diabetes as well. In 
general, increased cellular senescence is associated with the occurrence of cardiovascular 
diseases (30). As we consider gout as a chronic inflammatory disease with increased 
cellular senescence we, unsurprisingly, showed an association between telomere 
lengths and cardiovascular diseases in gout patients (chapter 8). Ideally, a marker to 
distinguish between gout patients with high and those with low cardiovascular risk 
should be discovered. Then only those gout patients with increased cardiovascular 
risk can be managed and followed-up intensively for other cardiovascular risk factors. 
Unfortunately in our studies we did not find a marker for cardiovascular risk and further 
studies identifying markers for cardiovascular risks in gout patients are needed. 
As hyperuricemia and gout are associated with the occurrence of cardiovascular diseases, 
treatment of hyperuricemia or gout will not only decrease the numbers of gout attacks, 
but could also decrease cardiovascular risk. Allopurinol already has shown cardiovascular 
protective effects, like improved endothelial function. Hypothetically the decrease of 
chronic systemic inflammation by allopurinol could be an explanation for its cardiovascular 
protective effects. Our pilot study (chapter 6) did not show that allopurinol decreased 
serum CXCL8 levels, but we did not investigate other inflammatory markers to explain 
the possible cardiovascular protective properties of allopurinol. We have demonstrated 
in chapter 8 that in gout patients shorter telomere length is associated with higher flare 
frequency and higher prevalence of cardiovascular diseases. Frequent local inflammation 
(flares) induced by MSU crystals might induce increased replicative senescence. This 
implies that prevention of gout flares by uric acid lowering therapy decreases replicative 
senescence and subsequently reduces the associated cardiovascular risk and other diseases 
of senescence (diabetes, cancer, infections) as well. However, this hypothesis must be 
further elaborated upon. Concluding, local inflammation (via increased replicative 
senescence) and systemic inflammation (via circulating proinflammatory cytokines) 
both associate with cardiovascular comorbidities. Prevention of local and systemic 
inflammation by uric acid lowering therapy can probably contribute to a reduction of 
cardiovascular risk. 
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Methodological considerations 
In this thesis we have used several study designs: case-control studies, cohort studies, 
and prospective diagnostic studies. All studies have been performed in daily clinical 
practice and this setting has the strength that the average gout patient has been included 
in our studies instead of the ideal study patient which is often included in for example 
randomized controlled trials. A limitation of this setting is that the internal validity might 
be less, because our research protocols were not as strict as in randomized controlled trials. 
Most of our studies have been performed with patients from a rheumatology outpatient 
clinic in a secondary care setting which makes the results of our study primarily valid for 
other secondary care patients, like patients visiting emergency departments or patients 
hospitalized at non-rheumatology departments. 
In the literature many studies use patients with self-reported gout or gout patients 
clinically diagnosed by a physician. This can lead to misclassification bias. A strength of 
this thesis is that we almost exclusively used MSU crystal-proven gout patients, except 
for some of the New Zealand patients included in the study described in chapter 6 who 
were diagnosed based on the 1977 ACR criteria, which have shown limited predictive 
values (14). 
Clinical implications of this thesis for the management of gout 
Our findings can have several implications for daily practice. The ideal future workup 
for a patient with an arthritis will be described in this paragraph. Most often these 
patients present themselves in primary care and at emergency departments, i.e. at 
locations where the gold standard of joint fluid analysis is not easily available. These 
physicians can use the gout decision rule to find out what the probability is that this 
patient has a gouty arthritis. 
If the patient scores low (a score ≤4) the physician should consider a different diagnosis 
than gout, such as CPPD arthritis, reactive arthritis, septic arthritis, rheumatoid 
arthritis, osteoarthritis or psoriatic arthritis. He can perform other diagnostic tests, such 
as laboratory tests or X-rays. 
If the patient scores intermediate (a score between 4 and 8) the physician should refer 
to a rheumatologist for joint aspiration and analysis of synovial fluid for identification 
of MSU crystals. He could also decide, when he is trained, to perform joint aspiration 
themselves and send the synovial fluid to the rheumatologist. The synovial fluid can be 
easily stored at refrigerator or freezer temperature without any additional conservation 
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process. After receiving the synovial fluid from the physician the rheumatologist or other 
trained expert analyzes it for presence of MSU crystals and he reports his findings to the 
physician. When MSU crystals are found and the diagnosis gout is made, the physician 
can treat the patient according to the guidelines for gout. 
If the patient scores high (a score ≥8) on the gout decision rule the physician could 
manage the patient as having gout and treat him according to the guidelines for gout. 
Management according to the guidelines for gout should include of course medications 
to treat the acute gout attack and if indicated to prevent future gout attacks, i.e. urate 
lowering therapy. But adequate management of gout patients should also include 
cardiovascular risk assessment. The cardiovascular risk can be assessed by the general 
guidelines for this. Considering the well-known association between gout and the 
occurrence of cardiovascular diseases, the presence of chronic systemic inflammation 
in gout patients (i.e. increased serum CXCL8 levels and shorter telomere lengths), the 
association between chronic systemic inflammation and the occurrence of cardiovascular 
diseases, and the cardiovascular protective effects of allopurinol the physician can decide 
to start urate lowering therapy in those gout patients with an increased cardiovascular 
risk, also if the patient does not meet the current criteria for this, in order to try to 
reduce the cardiovascular risk next to preventing gout flares. 
     
To conclude, in current daily practice good management of gout starts with a correct 
diagnosis and includes always care for increased cardiovascular risks.
Future perspective 
Gout is a challenging disease with many unanswered questions. This thesis gives rise 
to many research questions. This thesis has shown options on how the use of joint 
fluid analysis can be improved and how gout can be diagnosed reliably without the 
gold standard, even in secondary care patients (i.e. at emergency departments or other 
settings where facilities for joint fluid analysis are not available). The use of our presented 
algorithm for diagnosing gout, also in settings that the gold standard is not available, 
makes a reliable diagnosis for almost all gout patients available. Awareness about the 
limited validity of the diagnosis based on clinical signs and symptoms amongst all 
physicians who see patients with arthritis is necessary. The awareness can be enlarged 
by education of these physicians in how to diagnose gout reliably, but also by feedback 
in daily clinical practice if an arthritis suspected for gout turned out to be a different 
diagnosis after joint fluid analysis. Research on other – less expensive than polarization 
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microscopes – techniques could also help to make synovial fluid analysis more widely 
available. 
The gout decision rule should be further validated in oligo- and polyarthritis patients 
next to the monoarthritis patients in which the validity already has been shown. Also 
validation of the gout decision rule in patients from other countries as the Netherlands, 
where the health care system is different is needed. 
That chronic systemic inflammation is present in gout patients is a new finding, and 
in this thesis pioneer work on this research topic has been done. However, many more 
research is necessary for further understanding of how gout, cardiovascular diseases 
and chronic systemic inflammation are connected to each other. Especially prospective 
follow-up studies are needed to find out what the causal relationship between these three 
is. Measurement of pro-inflammatory cytokines (especially CXCL8) can obtain further 
insight in the behavior of chronic systemic inflammation over time. And, further research 
on prognostic markers (e.g. via the proteome of high and low CXCL8 levels (especially 
the protein MRP8/14 complex)) in larger groups of gout patients gives insight in the 
role of proteins in chronic systemic inflammation. At this moment it is unclear why 
uric acid crystallizes in one patient and not in another patient with the same condition 
and concentration of uric acid. Future studies on how to reduce cardiovascular risk in 
gout patients are necessary for adequate cardiovascular risk management. Therefore, 
more insight in the pathophysiology between gout, cardiovascular diseases and chronic 
systemic inflammation is necessary. Xanthine oxidase inhibition by allopurinol seems to 
reduce the cardiovascular risk, but the exact mechanism is not yet clear. A prospective 
study with gout patients treated with xanthine oxidase inhibition and gout patients 
treated with an uricosuricum can show what the role of xanthine oxidase in cardiovascular 
risk is. This thesis suggests that also decreasing chronic systemic inflammation in gout 
patients is promising in order to reduce cardiovascular risk. By reducing inflammation 
(i.e. the gout flare frequency) cellular senescence might be decreased, which can in the 
end lead to less cardiovascular risk. This can be investigated in a prospective study in 
which telomere length is measured in treated vs. untreated gout patients (and in low vs. 
high flare frequency) and the occurrence of cardiovascular diseases between both groups 
is assessed.
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Summary 
Gout is a common disease with a worldwide prevalence of 1-4%, caused by the 
deposition of monosodium urate (MSU) crystals in joints and soft tissue in patients 
with hyperuricemia. The disease is characterized by very painful recurrent attacks 
of arthritis. The most common clinical presentation is a monoarthritis of the first 
metatarsophalangeal (MTP1) joint. The gold standard for diagnosing gout is analysis 
of joint fluid (or tophaceous material), obtained via joint aspiration, for MSU 
crystals by using polarization light microscopy. Sufficient education and experience in 
performing joint aspiration and using polarization light microscopy is necessary for 
correct performance of this diagnostic test. Moreover, a polarization light microscope is 
expensive. In the Netherlands this diagnostic test is almost only done by rheumatologists. 
Most patients with gout present themselves in primary care and are (understandably) 
not referred to a rheumatologist. Because the therapeutic management depends on the 
right diagnosis, an accurate and valid diagnostic method is important. This applies to 
the diagnosis of gout, as well as in the case of the differential diagnosis, like rheumatoid 
arthritis.
In the last years it became clear that gout patients have an increased risk for suffering 
from or getting cardiovascular diseases. The underlying pathophysiological pathways 
are an important subject of research. The enzyme xanthine oxidase seems to play 
special role, because this enzyme converts hypoxanthine in uric acid, and associates 
with the release of free radicals. Free radicals induce oxidative stress in the vascular wall 
and lead to accelerated atherosclerosis and can in the end lead to more cardiovascular 
diseases. The cardiovascular protective effects of xanthine oxidase-inhibitor allopurinol, 
such as improvement of the endothelial function, supports this hypothesis. A different 
hypothesis is that in patients with gout, just as in for example rheumatoid arthritis, low-
grade chronic systemic inflammation is present. Notably, chronic systemic inflammation 
can lead to increased atherosclerosis and accelerated cellular senescence, which can lead 
to more cardiovascular diseases. In gout patients is known that for example the pro-
inflammatory cytokine interleukin (IL) 1β is increased in the affected joint during a 
gout attack. However, whether pro-inflammatory cytokines can be measured in serum 
of gout patients has never been researched. If the levels of these cytokines are increased, 
this could attribute to evidence that chronic systemic inflammation is present in gout 
patients. And if chronic systemic inflammation is present in gout patients, than this 
could be an additional link in the association with the increased cardiovascular risk.
The first part of this thesis focuses on obtaining more insight into a correct diagnosis of 
gout. Chapter 2 presents the results of a prospective follow-up study on the validity of 
the gout diagnosis by primary care physicians in patients with a monoarthritis of MTP1 
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(podagra). The primary care physician thought that gout was present in 98% of these 
patients, while in only 77% of them MSU crystals were found in an average follow-up 
period of 6 years. The existence of other rheumatic diseases in the MTP1 joint was 
nearly not considered. The differences in clinical signs and symptoms between gout 
and non-gout patients, such as an increased serum uric acid level and the presence of 
hypertension and/or cardiovascular diseases, may be useful to distinguish between both.
In chapter 3 the results are shown of a study on joint fluid analysis after long-term storage 
in varying conditions. A longstanding opinion is that joint fluid needs to be analyzed 
with polarization light microscopy rapidly after aspiration, because the formation and 
solubility of MSU crystals might be affected by pH and temperature. Our study showed 
that joint fluid can be easily stored at room or freezer temperature for half a year without 
loss of the diagnostic features of MSU crystals. Physicians, who are not trained in joint 
fluid analysis with polarization light microscopy or who don’t have a microscope (for 
example physicians in primary care or at emergency departments), could aspirate joint 
fluid and send this for microscopic analysis to a trained professional. 
In chapter 4 (and chapter 4a) the results of a prospective diagnostic study on validating 
a diagnostic decision rule for gout, without the need for MSU crystal identification, in 
a secondary care population are demonstrated. This diagnostic tool, originally designed 
for use in the primary care, consists of 6 clinical and 1 laboratory variable with weighted 
scores: male sex (2 points), previous arthritis attack (2 points), onset <1 day (0.5 point), 
joint redness (1 point), involvement of the MTP1 joint (2.5 points), hypertension or 
one or more cardiovascular disease (1.5 point), and serum uric acid >0.35 mmol/l (3.5 
points). A low score (≤4 points) implicates that the arthritis is non-gout in almost all 
(95%) of the patients. A high score (≥8 points) means that the arthritis is gout in 87% 
of the patients. In patients with a score between 4 and 8 there is uncertainty about the 
diagnosis. The positive predictive value of a score of ≥8 points was 0.87 and the negative 
predictive value of a score of ≤4 points was 0.95. The results in our secondary care 
population were similar compared to the results in the primary care study. The use of the 
diagnostic rule can lead to a quite reliable diagnosis in situations that polarization light 
microscopy is not available in secondary care. 
The second part of this thesis focuses on the presence of chronic systemic inflammation 
in gout patients and on the role of this inflammation in the association between gout 
and comorbidities such as cardiovascular diseases. Chapter 5 shows the results of 
research in which two gout patient cohorts from the Netherlands and one gout patient 
cohort from New Zealand are studied and compared to healthy controls and to patients 
with non-gouty inflammatory diseases. In serum of gout patients proinflammatory 
cytokines have been measured, and surprisingly the gout specific IL1β was not increased 
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but interestingly CXCL8 (IL8) was. Serum CXCL8 levels were clearly increased during 
a gout attack and during the intercritical phase (the asymptomatical period between 
two gout attacks) of the disease. From high serum CXCL8 levels is known that these 
can be associated with an increased cardiovascular risk. In this study we could not find 
an association between high serum CXCL8 levels and cardiovascular diseases in gout 
patients. By comparing the proteome of gout patients with high serum CXCL8 levels to 
those with low serum CXCL8 levels we found different proteins subsets between both. 
The protein MRP8/14 complex was most closely associated with the level of circulating 
CXCL8. The proteome of gout patients with high serum CXCL8 levels was associated 
with cardiovascular diseases and also with diabetes mellitus. Ideally, with comparable 
research, a prognostic marker would be identified to differentiate between gout patients 
with a high and low cardiovascular risk, in order to give gout patients with an increased 
risk extra or earlier cardiovascular risk management.
Research has been performed on the pathophysiology of the often discussed cardiovascular 
protective effect of allopurinol. After the finding that serum CXCL8 levels were increased 
in gout patients, we have studied in chapter 6 whether allopurinol could decrease these 
serum levels. We could not show that serum CXCL8 levels decreased by treatment with 
allopurinol in our pilot study with gout patients, but our follow-up period was short and 
not all patients reached an adequately lowered serum uric acid level. Further research is 
needed for a reliable answer to our research question.
Increased cellular senescence can lead to diseases of senescence, such as cardiovascular 
diseases. Cellular senescence can be measured by telomere length. Chapter 7 reveals the 
results of the measurement of telomere length in gout patients. Gout patients appeared to 
have shorter telomeres than healthy controls and shorter telomere length was associated 
with the number of gout attacks and the presence of cardiovascular diseases. Treatment 
of gout attacks could therefore theoretically decrease accelerated cellular senescence and 
the associated increased cardiovascular risk. This hypothesis should be further elaborated 
upon.
The thesis gives more insight in how gout can be correctly diagnosed. Patients with 
a MTP1 monoarthritis should be critically evaluated whether this is always gout. A 
diagnostic decision rule can be used to diagnose gout if joint fluid analysis is not available. 
If analysis with polarization light microscopy is not available directly after joint fluid 
aspiration, the joint fluid can also be stored at room or freezer temperature and send 
to a trained professional for microscopic analysis at a later moment. Further, this thesis 
has demonstrated the presence of chronic systemic inflammation, characterized by in 
particular increased serum CXCL8 levels, in gout patients. Also the presence of shorter 
telomere lengths suggesting accelerated cellular senescence in gout patients is shown and 
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that telomere length is associated with cardiovascular diseases. As final conclusion, gout 
patients deserve always a maximally correct diagnosis in order that they get the right 
therapeutic management, including adequate care for their evident high cardiovascular 
risks.
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Jicht is met een wereldwijde prevalentie van 1-4% een veelvoorkomende ziekte die 
wordt veroorzaakt door neerslag van natriumuraatkristallen in gewrichten en weke 
delen in patiënten met hyperuricemie. De ziekte kenmerkt zich door zeer pijnlijke, 
terugkerende aanvallen van acute artritis. De meest voorkomende klinische presentatie 
is een monoartritis van het eerste metatarsofalangeale (MTP1) gewricht. De gouden 
standaard om de diagnose jicht te stellen is onderzoek van gewrichtsvocht (of van 
tofeus materiaal), verkregen via een gewrichtspunctie, op natriumuraatkristallen met 
behulp van polarisatiemicroscopie. Voldoende scholing en ervaring in het verrichten van 
gewrichtspuncties en met het gebruik van polarisatiemicroscopie is noodzakelijk voor 
de juiste uitvoering van deze diagnostische test. Bovendien is een polarisatiemicroscoop 
duur. In Nederland wordt deze diagnostiek daarom vrijwel uitsluitend door reumatologen 
gedaan. De meeste patiënten met jicht presenteren zich echter bij de huisarts en worden 
(terecht) niet allemaal verwezen naar een reumatoloog. Omdat het therapeutische 
beleid afhangt van de juiste diagnose is het belangrijk is om een betrouwbare diagnose 
te stellen. Dit geldt zowel voor als de diagnose jicht is, als voor het geval dat er sprake is 
van een andere diagnose, zoals bijvoorbeeld reumatoïde artritis. 
In de laatste jaren is het duidelijk geworden dat jichtpatiënten een verhoogd risico 
hebben op het lijden aan of het krijgen van cardiovasculaire ziekten. De onderliggende 
pathofysiologische mechanismen zijn een belangrijk onderwerp voor onderzoek. Het 
enzym xanthine oxidase lijkt een speciale rol te spelen, omdat dit enzym hypoxanthine 
omzet in urinezuur en hierbij komen vrije zuurstofradicalen vrij. Vrije zuurstofradicalen 
induceren oxidatieve stress in de vaatwand en leiden op die manier tot meer atherosclerose 
en uiteindelijk tot meer cardiovasculaire ziekten. Het feit dat de xanthine oxidase-
remmer allopurinol cardiovasculair beschermende effecten heeft, zoals verbetering 
van de endotheelfunctie, ondersteunt deze hypothese. Een andere hypothese is dat bij 
patiënten met jicht, evenals bij bijvoorbeeld reumatoïde artritis, sprake is van laaggradige 
chronische systemische inflammatie. Van het bestaan van chronische systemische 
inflammatie is duidelijk dat dit leidt tot meer atherosclerose en versnelde veroudering 
van cellen, waardoor op die manier meer cardiovasculaire ziekten zouden kunnen 
ontstaan. Bij jichtpatiënten is bekend dat bijvoorbeeld het proinflammatoire cytokine 
interleukine (IL) 1β verhoogd is in het aangedane gewricht tijdens een jichtaanval. Echter, 
of ook in het serum van jichtpatiënten proinflammatoire cytokines te meten zijn is nooit 
onderzocht. Als de waardes van deze cytokines verhoogd zijn, zou dit een aanwijzing 
zijn voor het bestaan van chronische systemische inflammatie bij jichtpatiënten. En als 
er sprake is van chronische systemische inflammatie bij jichtpatiënten dan zou dat een 
verklaring kunnen zijn voor de associatie met cardiovasculaire ziekten.
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Het eerste deel van dit proefschrift richt zich op het verkrijgen van meer inzicht in hoe de 
diagnose jicht betrouwbaar kan worden gesteld. Hoofdstuk 2 presenteert de resultaten 
van een prospectieve follow-up studie waarin bij patiënten met een monoartritis van 
het MTP1 gewricht gekeken is wat de betrouwbaarheid van de diagnose jicht door de 
huisarts is. Hieruit bleek dat de huisarts in 98% van de gevallen dacht dat er sprake was 
van jicht gebaseerd op klinische kenmerken, terwijl bij slechts 77% van de patiënten 
natriumuraatkristallen konden worden aangetoond in een follow-up periode van 
gemiddeld 6 jaar. Het bestaan van andere reumatische ziektes in het MTP1 gewricht 
(geen jicht) werd nauwelijks overwogen. De verschillen in klinische kenmerken tussen 
jicht- en niet-jichtpatiënten, zoals een verhoogd serum urinezuur en de aanwezigheid van 
hypertensie en/of cardiovasculaire ziekten, konden helpen om het onderscheid te maken. 
In hoofdstuk 3 worden de resultaten getoond van onderzoek van gewrichtsvocht op 
natriumuraatkristallen na langdurige opslag onder diverse bewaarcondities. De algemene 
mening is dat gewrichtsvocht vers beoordeeld moet worden, direct na gewrichtspunctie, 
omdat de houdbaarheid van de natriumuraatkristallen beïnvloed zou kunnen worden 
door de pH en de temperatuur. Onze studie laat zien dat gewrichtsvocht eenvoudig 
bewaard kan worden bij koelkast- of vriezertemperatuur gedurende een half jaar zonder 
dat hierbij de diagnostische herkenbaarheid van de kristallen verslechtert. Artsen die niet 
geschoold en ervaren zijn in onderzoek van gewrichtsvocht met polarisatiemicroscopie 
of artsen die geen microscoop tot hun beschikking hebben (bijvoorbeeld huisartsen 
en SEH artsen) zouden gewrichtsvocht zelf kunnen aspireren en voor microscopisch 
onderzoek naar een getrainde professional kunnen opsturen.
In hoofdstuk 4 (en hoofdstuk 4a) worden de resultaten getoond van een prospectieve 
diagnostische studie waarbij een diagnostische beslisregel voor jicht, zonder dat daarbij 
het aantonen van natriumuraatkristallen nodig is, wordt gevalideerd in een tweedelijns 
setting. Bij de diagnostische beslisregel, die oorspronkelijk in een eerstelijns populatie 
is ontwikkeld, worden 6 klinische en 1 laboratorium variabele gewogen gescoord: 
mannelijk geslacht (2 punten), eerdere artritis aanval (2 punten), ontstaan binnen een 
dag (0,5 punt), roodheid van het gewricht (1 punt), MTP1 gewricht aangedaan (2,5 
punt), hypertensie of één of meer cardiovasculaire ziekte (1,5 punt) en serum urinezuur 
van >0,35 mmol/l (3,5 punt). Bij een score van ≤4 wordt de artritis niet door jicht 
veroorzaakt in 95% van de gevallen, bij een score ≥8 is er sprake van een jichtartritis 
in 87% van de gevallen en bij een score van 4-8 is de diagnose onduidelijk. De positief 
voorspellende waarde van een score van ≥8 punten was 0,87 en de negatief voorspellende 
waarde van een score ≤4 was 0,95. Deze resultaten in onze tweedelijns populatie waren 
vergelijkbaar met de resultaten in de eerstelijns setting. Het gebruik van de diagnostische 
beslisregel kan leiden tot een behoorlijk betrouwbare diagnose in situaties waarbij 
polarisatiemicroscopie in de tweede lijn niet beschikbaar is.
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In het tweede deel van dit proefschrift ligt de nadruk op onderzoek naar de aanwezigheid 
van chronische systemische inflammatie bij jichtpatiënten en naar de rol van deze 
inflammatie in de associatie tussen jicht en comorbiditeiten zoals cardiovasculaire 
ziekten. Hoofdstuk 5 laat de resultaten zien van een onderzoek waarbij twee 
jichtcohorten uit Nederland en een jichtcohort uit Nieuw-Zeeland worden bestudeerd 
en vergeleken met gezonde personen en met patiënten met andere inflammatoire ziektes 
(geen jicht). In het serum van jichtpatiënten zijn proinflammatoire cytokines gemeten 
waarbij opvallend genoeg het jichtspecifieke IL1β niet verhoogd was maar CXCL8 
(IL8) wel. Serum CXCL8 spiegels waren zowel tijdens een jichtaanval als daarbuiten 
in de rustige fase van de ziekte duidelijk verhoogd. Van hoge serum CXCL8 spiegels is 
in het algemeen bekend dat deze geassocieerd zouden kunnen zijn met een verhoogd 
cardiovasculair risico. In deze studie kon geen associatie gevonden worden tussen hoge 
serum CXCL8 spiegels en cardiovasculaire ziekten bij de onderzochte jichtpatiënten. 
Bij het vergelijken van het proteoom van jichtpatiënten met hoge serum CXCL8 
spiegels met die met lage serum CXCL8 spiegels zijn verschillende groepen van eiwitten 
gevonden. Het eiwit MRP8/14 complex was hierbij het meest geassocieerd met serum 
CXCL8 spiegel. Het proteoom van jichtpatiënten met hoge serum CXCL8 spiegels 
was geassocieerd met cardiovasculaire ziekten en ook met diabetes mellitus. Idealiter 
zou met vergelijkbaar onderzoek een prognostische marker gevonden worden waarmee 
gedifferentieerd kan worden tussen jichtpatiënten met een hoog en jichtpatiënten met 
een laag cardiovasculair risico, zodat jichtpatiënten met een verhoogd cardiovasculair 
risico extra of eerder cardiovasculaire zorg kunnen krijgen.
Hoe de pathofysiologie van de bekende cardiovasculaire beschermende werking van 
allopurinol in elkaar zit is niet geheel duidelijk. In aansluiting op de bevinding dat 
serum CXCL8 spiegels in jichtpatiënten verhoogd zijn, is in hoofdstuk 6 gekeken of 
allopurinol wellicht invloed op deze spiegels heeft. In de beschreven pilot studie kon niet 
worden aangetoond dat allopurinol serum CXCL8 spiegels liet dalen in jichtpatiënten, 
maar de follow-up periode was ook erg kort en niet alle patiënten bereikten een 
adequaat verlaagd serum urinezuur. Vervolgonderzoek om hier een goede uitspraak over 
te kunnen doen is nodig.
Van versnelde veroudering van cellen is bekend dat dit kan leiden tot meer 
verouderingsziekten waaronder cardiovasculaire ziekten. Veroudering van cellen is te 
meten via telomeerlengtes. Hoofdstuk 7 laat de resultaten zien van het meten van de 
lengte van het telomeer bij jichtpatiënten. Jichtpatiënten bleken kortere telomeren te 
hebben dan gezonde personen en de kortere telomeerlengte was geassocieerd met het 
aantal jichtaanvallen en de aanwezigheid van cardiovasculaire ziekten. Het behandelen 
van jichtaanvallen zou daarmee versnelde celveroudering en het geassocieerde vergrote 
cardiovasculaire risico kunnen verminderen, maar deze hypothese moet verder 
onderzocht worden.
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Dit proefschrift geeft inzicht in hoe de diagnose jicht betrouwbaar kan worden gesteld. 
Bij patiënten met een MTP1 monoartritis moeten kritisch gekeken blijven worden of 
dit daadwerkelijk jicht is. In de tweede lijn kan een diagnostische beslisregel gebruikt 
worden om de diagnose jicht te stellen of uit te sluiten indien microscopisch onderzoek 
van gewrichtsvocht op natriumuraatkristallen niet mogelijk is. Ook kan gewrichtsvocht, 
indien onderzoek naar natriumuraatkristallen niet direct aansluitend op de aspiratie 
mogelijk is, opgeslagen worden bij kamer- of vriezertemperatuur en opgestuurd worden 
naar een getrainde professional voor onderzoek op een later moment. Verder heeft dit 
proefschrift de aanwezigheid van chronische systemische inflammatie, gekenmerkt 
door de aanwezigheid van met name verhoogde serum CXCL8 levels, aangetoond 
in jichtpatiënten. Ook is laten zien dat er bij jichtpatiënten sprake is van versnelde 
celveroudering via verkorte telomeerlengtes en dat dit geassocieerd is met cardiovasculaire 
ziekten. Concluderend, jichtpatiënten verdienen een maximaal betrouwbare diagnose 
zodat ze de juiste therapie, inclusief adequate cardiovasculaire screening en follow-up, 
krijgen. 
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List of abbreviations
CI   confidence interval
CRP   C-reactive protein
CVD   cardiovascular diseases
CBA   Cytometric Bead Array
GFR   glomerular filtration rate
GP   general practitioner
hTERT   human telomerase reverse transcriptase
IL   interleukin
IQR   interquartile range
MRP   myeloid-related protein
MSU   monosodium urate
MTP1 joint  first metatarsophalangeal joint
NET   neutrophil extracellular trap
NK   natural killer
NSAID   non-steroidal anti-inflammatory drug
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OR   odds ratio
PBMC   peripheral blood mononuclear cell
pDCs   plasmacytoid dendritic cells
PE   phycoerythrin
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RA   rheumatoid arthritis
ROC curve  receiver operator characteristics curve
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mass spectrometry
SD   standard deviation
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VSMC   vascular smooth muscle cells
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